A species of gram-negative, aerobic bacteria that is the causative agent of WHOOPING COUGH. Its cells are minute coccobacilli that are surrounded by a slime sheath.
A genus of gram-negative, aerobic bacteria whose cells are minute coccobacilli. It consists of both parasitic and pathogenic species.
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Infections with bacteria of the genus BORDETELLA.
A species of BORDETELLA that is parasitic and pathogenic. It is found in the respiratory tract of domestic and wild mammalian animals and can be transmitted from animals to man. It is a common cause of bronchopneumonia in lower animals.
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
A set of BACTERIAL ADHESINS and TOXINS, BIOLOGICAL produced by BORDETELLA organisms that determine the pathogenesis of BORDETELLA INFECTIONS, such as WHOOPING COUGH. They include filamentous hemagglutinin; FIMBRIAE PROTEINS; pertactin; PERTUSSIS TOXIN; ADENYLATE CYCLASE TOXIN; dermonecrotic toxin; tracheal cytotoxin; Bordetella LIPOPOLYSACCHARIDES; and tracheal colonization factor.
One of the virulence factors produced by BORDETELLA PERTUSSIS. It is a multimeric protein composed of five subunits S1 - S5. S1 contains mono ADPribose transferase activity.
A species of BORDETELLA with similar morphology to BORDETELLA PERTUSSIS, but growth is more rapid. It is found only in the RESPIRATORY TRACT of humans.
Agents that cause agglutination of red blood cells. They include antibodies, blood group antigens, lectins, autoimmune factors, bacterial, viral, or parasitic blood agglutinins, etc.
One of the virulence factors produced by virulent BORDETELLA organisms. It is a bifunctional protein with both ADENYLYL CYCLASES and hemolysin components.
A species of BORDETELLA isolated from the respiratory tracts of TURKEYS and other BIRDS. It causes a highly contagious bordetellosis.
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Cell-surface components or appendages of bacteria that facilitate adhesion (BACTERIAL ADHESION) to other cells or to inanimate surfaces. Most fimbriae (FIMBRIAE, BACTERIAL) of gram-negative bacteria function as adhesins, but in many cases it is a minor subunit protein at the tip of the fimbriae that is the actual adhesin. In gram-positive bacteria, a protein or polysaccharide surface layer serves as the specific adhesin. What is sometimes called polymeric adhesin (BIOFILMS) is distinct from protein adhesin.
An enzyme of the lyase class that catalyzes the formation of CYCLIC AMP and pyrophosphate from ATP. EC
A transient increase in the number of leukocytes in a body fluid.
Substances, usually of biological origin, that cause cells or other organic particles to aggregate and stick to each other. They include those ANTIBODIES which cause aggregation or agglutination of particulate or insoluble ANTIGENS.
Proteins isolated from the outer membrane of Gram-negative bacteria.
Proteins found in any species of bacterium.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
The top portion of the pharynx situated posterior to the nose and superior to the SOFT PALATE. The nasopharynx is the posterior extension of the nasal cavities and has a respiratory function.
Substances elaborated by bacteria that have antigenic activity.
Preparations of pathogenic organisms or their derivatives made nontoxic and intended for active immunologic prophylaxis. They include deactivated toxins. Anatoxin toxoids are distinct from anatoxins that are TROPANES found in CYANOBACTERIA.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The functional hereditary units of BACTERIA.
The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.
Excess of normal lymphocytes in the blood or in any effusion.
Any of the processes by which cytoplasmic or intercellular factors influence the differential control of gene action in bacteria.
Deoxyribonucleic acid that makes up the genetic material of bacteria.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Physicochemical property of fimbriated (FIMBRIAE, BACTERIAL) and non-fimbriated bacteria of attaching to cells, tissue, and nonbiological surfaces. It is a factor in bacterial colonization and pathogenicity.
Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Tests that are dependent on the clumping of cells, microorganisms, or particles when mixed with specific antiserum. (From Stedman, 26th ed)
Thin, hairlike appendages, 1 to 20 microns in length and often occurring in large numbers, present on the cells of gram-negative bacteria, particularly Enterobacteriaceae and Neisseria. Unlike flagella, they do not possess motility, but being protein (pilin) in nature, they possess antigenic and hemagglutinating properties. They are of medical importance because some fimbriae mediate the attachment of bacteria to cells via adhesins (ADHESINS, BACTERIAL). Bacterial fimbriae refer to common pili, to be distinguished from the preferred use of "pili", which is confined to sex pili (PILI, SEX).
The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.
The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi.
A chronic inflammation in which the NASAL MUCOSA gradually changes from a functional to a non-functional lining without mucociliary clearance. It is often accompanied by degradation of the bony TURBINATES, and the foul-smelling mucus which forms a greenish crust (ozena).
Regulatory proteins that act as molecular switches. They control a wide range of biological processes including: receptor signaling, intracellular signal transduction pathways, and protein synthesis. Their activity is regulated by factors that control their ability to bind to and hydrolyze GTP to GDP. EC 3.6.1.-.
Toxic substances formed in or elaborated by bacteria; they are usually proteins with high molecular weight and antigenicity; some are used as antibiotics and some to skin test for the presence of or susceptibility to certain diseases.
An ester formed between the aldehydic carbon of RIBOSE and the terminal phosphate of ADENOSINE DIPHOSPHATE. It is produced by the hydrolysis of nicotinamide-adenine dinucleotide (NAD) by a variety of enzymes, some of which transfer an ADP-ribosyl group to target proteins.
The tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Proteins from BACTERIA and FUNGI that are soluble enough to be secreted to target ERYTHROCYTES and insert into the membrane to form beta-barrel pores. Biosynthesis may be regulated by HEMOLYSIN FACTORS.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Antisera from immunized animals that is purified and used as a passive immunizing agent against specific BACTERIAL TOXINS.
An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
Discrete segments of DNA which can excise and reintegrate to another site in the genome. Most are inactive, i.e., have not been found to exist outside the integrated state. DNA transposable elements include bacterial IS (insertion sequence) elements, Tn elements, the maize controlling elements Ac and Ds, Drosophila P, gypsy, and pogo elements, the human Tigger elements and the Tc and mariner elements which are found throughout the animal kingdom.

Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells. (1/1244)

Immunization with whole-cell pertussis vaccines (WCV) containing heat-killed Bordetella pertussis cells and with acellular vaccines containing genetically or chemically detoxified pertussis toxin (PT) in combination with filamentous hemagglutinin (FHA), pertactin (Prn), or fimbriae confers protection in humans and animals against B. pertussis infection. In an earlier study we demonstrated that FHA is involved in the adherence of these bacteria to human bronchial epithelial cells. In the present study we investigated whether mouse antibodies directed against B. pertussis FHA, PTg, Prn, and fimbriae, or against two other surface molecules, lipopolysaccharide (LPS) and the 40-kDa outer membrane porin protein (OMP), that are not involved in bacterial adherence, were able to block adherence of B. pertussis and B. parapertussis to human bronchial epithelial cells. All antibodies studied inhibited the adherence of B. pertussis to these epithelial cells and were equally effective in this respect. Only antibodies against LPS and 40-kDa OMP affected the adherence of B. parapertussis to epithelial cells. We conclude that antibodies which recognize surface structures on B. pertussis or on B. parapertussis can inhibit adherence of the bacteria to bronchial epithelial cells, irrespective whether these structures play a role in adherence of the bacteria to these cells.  (+info)

Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. (2/1244)

During colonization of the respiratory tract by Bordetella pertussis, virulence factors contribute to adherence of the bacterium to the respiratory tract epithelium. In the present study, we examined the roles of the virulence factors filamentous hemagglutinin (FHA), fimbriae, pertactin (Prn), and pertussis toxin (PT) in the adherence of B. pertussis to cells of the human bronchial epithelial cell line NCI-H292 and of the laryngeal epithelial cell line HEp-2. Using B. pertussis mutant strains and purified FHA, fimbriae, Prn, and PT, we demonstrated that both fimbriae and FHA are involved in the adhesion of B. pertussis to laryngeal epithelial cells, whereas only FHA is involved in the adherence to bronchial epithelial cells. For PT and Prn, no role as adhesion factor was found. However, purified PT bound to both bronchial and laryngeal cells and as such reduced the adherence of B. pertussis to these cells. These data may imply that fimbriae play a role in infection of only the laryngeal mucosa, while FHA is the major factor in colonization of the entire respiratory tract.  (+info)

Characterization of human bactericidal antibodies to Bordetella pertussis. (3/1244)

The Bordetella pertussis BrkA protein protects against the bactericidal activity of complement and antibody; however, some individuals mount an immune response that overcomes this bacterial defense. To further characterize this process, the bactericidal activities of sera from 13 adults with different modes of exposure to B. pertussis (infected as adults, occupational exposure, immunized with an acellular vaccine, or no identified exposure) against a wild-type strain and a BrkA complement-sensitive mutant were evaluated. All of the sera killed the BrkA mutant, suggesting past exposure to B. pertussis or cross-reactive organisms. Several samples had no or minimal activity against the wild type. All of the sera collected from the infected and occupationally exposed individuals but not all of the sera from vaccinated individuals had bactericidal activity against the wild-type strain, suggesting that some types of exposure can induce an immune response that can overcome the BrkA resistance mechanism. Adsorbing serum with the wild-type strain removed the bactericidal antibodies; however, adsorbing the serum with a lipopolysaccharide (LPS) mutant or an avirulent (bvg mutant) strain did not always result in loss of bactericidal activity, suggesting that antibodies to either LPS or bvg-regulated proteins could be bactericidal. All the samples, including those that lacked bactericidal activity, contained antibodies that recognized the LPS of B. pertussis. Bactericidal activity correlated best with the presence of the immunoglobulin G3 (IgG3) antibodies to LPS, the IgG subtype that is most effective at fixing complement.  (+info)

Maternal immunization. (4/1244)

Maternal immunization can enhance passive immunity of infants to pathogens that cause life-threatening illnesses. In most instances, immunization during pregnancy will provide important protection for the woman as well as for her offspring. The tetanus toxoid and influenza vaccines are examples of vaccines that provide a double benefit. Other vaccines under evaluation include those for respiratory syncytial virus, pneumococci, group B streptococci, and Haemophilus influenzae type b. Although most IgG antibody crosses the placenta in the third trimester, the process is time-dependent, dictating that immunization should be accomplished ideally at least 6 weeks prior to delivery. IgG1 antibodies are transferred preferentially. Maternal immunization has not interfered with active immunization of the infant. Inactivated vaccines administered in the third trimester of pregnancy pose no known risk to the woman or to her fetus.  (+info)

Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. (5/1244)

The population structure of Bordetella pertussis in The Netherlands in 5 successive periods, encompassing 1949-1996, was analyzed by DNA typing ("fingerprinting"). In 10 years following the introduction of wide-scale vaccination in 1953, a decrease in genotypic diversity (GD) was observed, suggesting clonal expansion of strains that were adapted to vaccine-induced immunity. In subsequent periods, GD increased to prevaccination levels, probably reflecting a gradual adaptation of the B. pertussis population involving many lineages. In the 1990s, GD decreased again. This decrease coincided with an antigenic shift in the surface protein pertactin. No evidence was found for changes in DNA types or GD in 1996, when a large pertussis epidemic occurred. Thus, gradual changes in the bacterial population previous to 1996 were probably the cause of the 1996 epidemic. The results herein suggest that vaccination has selected for strains that are adapted to a highly vaccinated population. Similar changes may have occurred in other countries, explaining the reemergence of pertussis in vaccinated populations.  (+info)

Analysis with a combination of macrorestriction endonucleases reveals a high degree of polymorphism among Bordetella pertussis isolates in eastern France. (6/1244)

From 1990 to 1996, routine screening for whooping cough identified 399 patients with a calmodulin-dependent adenylate cyclase-positive test result and yielded 69 Bordetella pertussis isolates. None of the patients were fully vaccinated, and most were less than 6 months old. Analysis of total DNA by pulsed-field gel electrophoresis (PFGE) after XbaI, SpeI, or DraI macrorestriction yielded 19, 15, and 5 different patterns, respectively, whereas ribotyping failed to demonstrate any strain polymorphism. Discrimination among the isolates was improved by combining the PFGE profiles. Some patterns were more frequent, but the corresponding patients were not clearly epidemiologically related. The patterns for two strains obtained during a 3-month period from patients who were neighbors differed by the length of a single DNA fragment. These data strongly suggest that one type of isolate is widely spread throughout the world and is carried by individuals other than patients who develop a true illness.  (+info)

Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. (7/1244)

Levels of IgG antibody to pertussis toxin (PT) and filamentous hemagglutinin (FHA) were measured in paired serum samples from 781 patients fulfilling at least one laboratory criterion for pertussis that was suggested by an ad hoc committee sponsored by the World Health Organization. The patients were participants or family members of participants in a double-blind efficacy trial of a monocomponent pertussis toxoid vaccine. Of 596 nonvaccinated children, 90% had significant (two-fold or more) rises in PT IgG and FHA IgG levels. Only 17 (32%) of 53 children previously vaccinated with three doses of pertussis toxoid had rises in PT IgG levels because they already had elevated PT IgG levels in their acute-phase serum samples. PT IgG and FHA IgG levels were significantly higher in acute-phase serum samples from 29 adults than in acute-phase serum samples from the nonvaccinated children. Nevertheless, significant rises in levels of PT IgG (79% of samples) and FHA IgG (90%) were demonstrated in adults. In conclusion, assay of PT IgG and FHA IgG in paired serum samples is highly sensitive for diagnosing pertussis in nonvaccinated individuals. Assay of PT IgG levels in paired sera is significantly less sensitive for diagnosis of pertussis for children vaccinated with pertussis toxoid.  (+info)

The conserved lysine 860 in the additional fatty-acylation site of Bordetella pertussis adenylate cyclase is crucial for toxin function independently of its acylation status. (8/1244)

The Bordetella pertussis RTX (repeat in toxin family protein) adenylate cyclase toxin-hemolysin (ACT) acquires biological activity upon a single amide-linked palmitoylation of the epsilon-amino group of lysine 983 (Lys983) by the accessory fatty-acyltransferase CyaC. However, an additional conserved RTX acylation site can be identified in ACT at lysine 860 (Lys860), and this residue becomes palmitoylated when recombinant ACT (r-Ec-ACT) is produced together with CyaC in Escherichia coli K12. We have eliminated this additional acylation site by replacing Lys860 of ACT with arginine, leucine, and cysteine residues. Two-dimensional gel electrophoresis and microcapillary high performance liquid chromatography/tandem mass spectrometric analyses of mutant proteins confirmed that the two sites are acylated independently in vivo and that mutations of Lys860 did not affect the quantitative acylation of Lys983 by palmitoyl (C16:0) and palmitoleil (cis Delta9 C16:1) fatty-acyl groups. Nevertheless, even the most conservative substitution of lysine 860 by an arginine residue caused a 10-fold decrease of toxin activity. This resulted from a 5-fold reduction of cell association capacity and a further 2-fold reduction in cell penetration efficiency of the membrane-bound K860R toxin. These results suggest that lysine 860 plays by itself a crucial structural role in membrane insertion and translocation of the toxin, independently of its acylation status.  (+info)

Bordetella pertussis adenylate cyclase. Penetration into host cells.: Exposure of Chinese hamster ovary, mouse adrenal cortex tumor (Y-1), THP-1 and U-937 cells
The Bordetella pertussis calmodulin-dependent adenylate cyclase (CyaA) is a 1706-residue-long toxin, endowed with hemolytic activity. We have constructed B.
The effect of an i.p. injection of Bordetella pertussis on the primary humoral immune response in mice to the thymus-independent antigen SIII has been studied. Suppression of the antibody response occurred when pertussis cells were injected at the same time as an optimal immunizing dose of SIII. In contrast, the antibody response to high doses of SIII was enhanced by B. pertussis.. When SIII alone was injected, only 19S antibody was detected. However, when B. pertussis was administered with either optimal or high doses of SIII, 7S as well as 19S antibody against SIII was produced.. ...
Bordetella pertussis isolates that do not express pertactin (PRN) are increasing in regions where acellular pertussis vaccines have been used for >7 years. We analyzed data from France and compared clinical symptoms among infants <6 months old infected by PRN-positive or PRN-negative isolates. No major clinical differences were found between the 2 groups.
Bordetella pertussis is the causative agent of human whooping cough (pertussis) and is particularly severe in infants. Despite worldwide vaccinations, whooping cough remains a public health problem. A significant increase in the incidence of whooping cough has been observed in many countries since the 1990s. Several reasons for the re-emergence of this highly contagious disease have been suggested. A particularly intriguing possibility is based on evidence indicating that pathogen adaptation may play a role in this process. In an attempt to gain insight into the genomic make-up of B. pertussis over the last 60 years, we used an oligonucleotide DNA microarray to compare the genomic contents of a collection of 171 strains of B. pertussis isolates from different countries. The CGH microarray analysis estimated the core genome of B. pertussis, to consist of 3,281 CDSs that are conserved among all B. pertussis strains, and represent 84.8% of all CDSs found in the 171 B. pertussis strains. A total of 64
Morse, J.H.; Kong, A.S.; Lindenbaum, J.; Morse, S.I., 1977: The mitogenic effect of the lymphocytosis promoting factor from Bordetella pertussis on human lymphocytes
The effect of exogenously added adenylate cyclase from Bordetella pertussis (strain 114) has been investigated in Y-1 mouse adrenal tumor, chinese hamster ovary (CHO) and several other cells. A partially purified adenylate cyclase was found not to enter cells but, nevertheless, produced large amounts of cAMP in the medium. We could show that this resulted from release of ATP (and not larger molecules). The ATP released by the cells could be (1) directly measured and was replenished after each change of medium; (2) was reciprocally related to the cAMP produced; and (3) was competed for by ATPases present in added serum or by hexokinase and, less effectively, by exoenzymes on the cell surface. The extent of ATP leakage varied widely between different cell lines, being marked in CHO and Y-1 adrenal cells but negligible in transformed lymphocyte lines. The uncertainty of the origin of cAMP found in media of cultured cells requires separate analysis of cell and medium cAMP and an assessment of ATP ...
Since the 1980s, pertussis notifications in the United States have been increasing. To determine the types of Bordetella pertussis responsible for these increases, we divided 661 B. pertussis isolates collected in the United States during 1935-2009 into 8 periods related to the introduction of novel vaccines or changes in vaccination schedule. B. pertussis diversity was highest from 1970-1990 (94%) but declined to ≈ 70% after 1991 and has remained constant. During 2006-2009, 81.6% of the strains encoded multilocus sequence type prn2-ptxP3-ptxS1A-fim3B, and 64% were multilocus variable number tandem repeat analysis type 27. US trends were consistent with those seen internationally; emergence and predominance of the fim3B allele was the only molecular characteristic associated with the increase in pertussis notifications. Changes in the vaccine composition and schedule were not the direct selection pressures that resulted in the allele changes present in the current B. pertussis population ...
Acellular vaccines against Bordetella pertussis were introduced in Australia in 1997. By 2000, these vaccines had replaced whole-cell vaccines. During 2008-2012, a large outbreak of pertussis occurred. During this period, 30% (96/320) of B. pertussis isolates did not express the vaccine antigen pertactin (prn). Multiple mechanisms of prn inactivation were documented, including IS481 and IS1002 disruptions, a variation within a homopolymeric tract, and deletion of the prn gene. The mechanism of lack of expression of prn in 16 (17%) isolates could not be determined at the sequence level. These findings suggest that B. pertussis not expressing prn arose independently multiple times since 2008, rather than by expansion of a single prn-negative clone. All but 1 isolate had ptxA1, prn2, and ptxP3, the alleles representative of currently circulating strains in Australia. This pattern is consistent with continuing evolution of B. pertussis in response to vaccine selection pressure.
The genus Bordetella consists of Gram-negative β-proteobacteria, including the three human pathogens Bordetella pertussis, Bordetella parapertussis an...
TY - JOUR. T1 - Surveillance of circulating bordetella pertussis strains in Europe during 1998 to 2015. AU - Barkoff, Alex Mikael. AU - Mertsola, Jussi. AU - Pierard, Denis. AU - Dalby, Tine. AU - Hoegh, Silje Vermedal. AU - Guillot, Sophie. AU - Stefanelli, Paola. AU - Van Gent, Marjolein. AU - Berbers, Guy. AU - Vestrheim, Didrik F.. AU - Greve-Isdahl, Margrethe. AU - Wehlin, Lena. AU - Ljungman, Margaretha. AU - Fry, Norman. AU - Markey, Kevin. AU - Auranen, Kari. AU - Hea, Qiushui. N1 - Funding Information: eDepartment of Clinical Microbiology, Odense, University Hospital, Odense, Denmark fNational Reference Center of Whooping Cough and Other Bordetelloses, Institut Pasteur, Paris, France gDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy hCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands Publisher Copyright: Copyright © 2018 American Society for Microbiology. All Rights ...
Bordetella pertussis infection is being increasingly recognized as a cause of prolonged, distressing cough (without whooping symptoms) in children and young adults. Diagnosis of infection in this population is important for treatment and surveillance purposes, and may also prove useful in reducing transmission to unvaccinated babies, for whom disease can be fatal. Serum IgG titres against pertussis toxin (PT) are routinely used as a marker of recent or persisting B. pertussis infection. However, collection of serum from young children is difficult, and compliance amongst these subjects to give samples is low. To circumvent these problems, an IgG-capture ELISA capable of detecting anti-PT IgG in oral fluid was devised. The assay was evaluated by comparison to a serum ELISA, using 187 matched serum and oral fluid samples from children (aged 5-16 years) with a history of prolonged coughing, whose serum anti-PT titre had already been determined (69 seropositive, 118 seronegative). The results showed that,
Bordetella pertussis is an aerobic gram-negative bacterial pathogen that causes the human respiratory disease whooping cough. Despite widespread vaccination, whooping cough is reemerging due to decreased vaccine efficacy. One of the hallmarks of infection is lymphocytosis, which is induced by the pertussis toxin. Lymphocytes such as CD4+ T cells navigate to infected tissues through surface-trafficking molecules, which are imprinted during their interaction with tissue-associated dendritic cells. We hypothesized that the pertussis toxin affects the imprinting process resulting in altered expression of trafficking molecules on CD4+ T cells. We tested this hypothesis using a mouse model of infection. Imprinting levels on CD4+ T cells were compared to Bordetella parapertussis, a related strain that lacks pertussis toxin. Our results indicated that 5 days post-infection, the percentage of lung dendritic cells increased and adopted a mature phenotype (displaying an increased capability to migrate and present
TY - JOUR. T1 - Intracellular survival of virulent Bordetella pertussis in human polymorphonuclear leukocytes. AU - Steed, L. L.. AU - Setareh, M.. AU - Friedman, R. L.. PY - 1991/1/1. Y1 - 1991/1/1. N2 - Little is known regarding the interaction of Bordetella pertussis with polymorphonuclear leukocytes (PMNL) or the role PMNL play as an initial line of defense against B. pertussis infection. An in vitro system was developed to establish conditions for the study of phagocytosis and killing of virulent B. pertussis by human PMNL. Phagocytosis of B. pertussis strains BP504, BP165, and BP338 occurred by opsonization with anti-B. pertussis antibody, while autologous normal human sera did not induce significant phagocytosis. In PMNL bacterial killing assays virulent B. pertussis strains survived PMNL bactericidal activities while Escherichia coli controls were readily killed. Electron microscopy studies using acid phosphatase as a lysosomal marker strongly suggested that B. pertussis inhibits ...
Bordetella pertussis is a strict human pathogen that is the causative agent of pertussis (whooping cough). Despite widespread immunization with pertussis vaccines, many countries still report outbreaks (1, 12, 14). Resurgence of pertussis has been recently observed in some countries with high vaccination coverage (4, 8, 10). It is suggested that pathogen adaptation may play a role in the reemergence of pertussis (10, 15, 16). In this present work, the complete genome sequence of B. pertussis strain CS, which was isolated from an infant patient in 1951 in Beijing and widely used as a vaccine strain for production of an acellular pertussis vaccine in China, was determined and compared with the published genome of Tohama I (11).. Whole-genome sequencing of B. pertussis CS was performed with a combined strategy of the Sanger shotgun approach (6) and 454 fragment sequencing technology (9). A total of 329,480 reads, giving 28-fold coverage of the genome, were generated using the GS FLX system (454 ...
Bordetella pertussis ATCC ® BAA-589D-5™ Designation: Genomic DNA from Bordetella pertussis Strain Tohama 1 TypeStrain=False Application:
The Global and Chinese Bordetella Pertussis Industry, 2011-2021 Market Research Report is a professional and in-depth study on the current state of the global Bordetella Pertussis industry with a focus on the Chinese market. The report provides key statistics on the market status of the Bordetella Pertussis manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.. Complete report of 150 pages published in Jan 2016 is available at http://www.market-research-reports.com/434778-bordetella-pertussis-industry.. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2011-2016 market shares for each company. Through the statistical analysis, the report depicts the ...
BACKGROUND: Each year, Bordetella pertussis infection causes an estimated 294,000 deaths worldwide, primarily among young, nonvaccinated children. Approximately 90% of all deaths due to pertussis in the Unites States occur in young infants. These children often develop intractable pulmonary hypertension; however, the pathophysiologic mechanism responsible for this complication has not been well characterized, and there have been no detailed descriptions of the pathology of this disease since the 1940s.. METHODS: Respiratory tissue samples obtained at autopsy from 15 infants aged ,or=4 months who had polymerase chain reaction- or culture-confirmed B. pertussis pneumonia were evaluated by multiple histochemical stains, immunohistochemical evaluation, and electron microscopic examination.. RESULTS: The pulmonary histopathologic examination of the samples revealed a descending infection dominated by necrotizing bronchiolitis, intra-alveolar hemorrhage, and fibrinous edema. All samples had marked ...
Catalyzes the rearrangement of 1-deoxy-D-xylulose 5-phosphate (DXP) to produce the thiazole phosphate moiety of thiamine. Sulfur is provided by the thiocarboxylate moiety of the carrier protein ThiS. In vitro, sulfur can be provided by H(2)S.
Intranasal immunization of adult female Balb/c mice with the Bordetella pertussis antigens FHA or P.69, greatly enhanced their ability to clear B. pertussis from their lungs following aerosol challenge compared with ovalbumin-immunized controls. Low numbers of lymphocytes secreting antibodies (IgG, …
In order to achieve batch-to-batch consistency of whole-cell pertussis vaccines, properties relevant for protection and safety should be characterised. Therefore, ELISAs to quantify pertussis toxin (PT), filamentous haemagglutinin (FHA), 92 kD outer membrane protein (92 kD-OMP) and pertactin (PRN) in Bordetella pertussis (B. pertussis) suspensions were developed. In this paper the influence of the bacterial growth stage on antigen production and antigen release into the supernatant was studied for pertussis strains 134, 509 and CS. The levels of cell-associated and free antigens during growth were strongly strain and antigen dependent. Because of this, the proportion of cell-associated antigens changed during cultivation for all three strains. Substantial amounts of PT and PRN were released into the supernatant, while little free FHA and 92 kD-OMP were found. The amount of cell-associated FHA declined rapidly during growth, whereas cell-associated 92 kD-OMP contents increased. These findings ...
OBJECTIVE: To study the clinical presentation of culture-confirmed pertussis in children and their contacts with cough illnesses in an outpatient setting. METHODOLOGY: In conjunction with a large pertussis vaccine efficacy trial in Germany, a central laboratory to isolate Bordetella species from nasopharyngeal specimens was established in Erlangen in October 1990. Pediatricians in private practices in southern Germany, the Saar region, and Berlin were encouraged to obtain nasopharyngeal specimens and clinical characteristics from patients with cough illnesses ,/=7 days duration. Bordetella species were isolated by use of calcium alginate swabs, Regan-Lowe agar, and modified Stainer-Scholte broth. Clinical characteristics were determined by initial and follow-up questionnaires. RESULTS: From October 1990 to September 1996, 20 972 specimens were submitted, and B pertussis was isolated in 2592 instances (12.4%). Of the culture-proven cases, 50.7% were female, and the age range was 6 days to 41 ...
Bordetella pertussis, small coccoid gram-negative rod-shaped bacteria, is the causative agent of pertussis, a respiratory disease. The bacteria are transmitted by droplet infection from individual to individual. The disease mainly affects children in the age of 0-4 years. It shows a high lethality in newborns. The Immunolab Bordetella pertussis IgG/IgM/IgA ELISAs are quantitative and qualitative tests for the…
Background. Acellular pertussis (aP) booster immunizations have been recommended for adolescents and older persons to enhance long-term protection and to possibly reduce community transmission of infections.. Methods. This was a multicenter, randomized, double-blind vaccine trial in which one-half of the subjects received aP vaccine and one-half received hepatitis A vaccine (control subjects). All subjects were observed for almost 2 years for cough illnesses, and all underwent microbiologic and serologic studies for detection of pertussis infection. Immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae 2/3 were measured by enzyme-linked immunosorbent assay in serum samples obtained 1 and 12 months after immunization. Infection rates were determined with a variety of serologic criteria for control and vaccinated subjects. The incidence of prolonged cough illness was ascertained for subjects with and subjects without ...
GENTILE, Ángela et al. Cost of Bordetella pertussis illness in tertiary hospitals in Argentina. Arch. argent. pediatr. [online]. 2013, vol.111, n.4, pp.295-302. ISSN 0325-0075. http://dx.doi.org/10.5546/aap.2013.295.. The National Immunization Commission and the National Program for the Control of Vaccine-Preventable Diseases (Programa Nacional de Control de Enfermedades Inmunoprevenibles, ProNaCEI) updated the immunization policy in relation to Bordetella pertussis (BP) in 2009 in order to improve the control of this disease in accordance with international recommendations. To evaluate the fnancial impact of this new immunization policy, we must frst know the cost on the health system of having a hospitalized or outpatient child infected with BP. The objective of this study was to describe the profle of costs of hospitalized or outpatient children with laboratory-confrmed BP infection in three hospitals of Argentina. This was a prospective study of the cost of BP in the period between December ...
ID BOPER1_1_PE1000 STANDARD; PRT; 266 AA. AC BOPER1_1_PE1000; Q7VZ03; DT 00-JAN-0000 (Rel. 1, Created) DT 00-JAN-0000 (Rel. 2, Last sequence update) DT 00-JAN-0000 (Rel. 3, Last annotation update) DE SubName: Full=Competence lipoprotein; (BOPER1_1.PE1000). GN Name=comL; OrderedLocusNames=BP1146; OS BORDETELLA PERTUSSIS TOHAMA I. OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales; OC Alcaligenaceae; Bordetella. OX NCBI_TaxID=257313; RN [0] RP -.; RG -.; RL -.; CC -!- SEQ. DATA ORIGIN: Translated from the HOGENOM CDS BOPER1_1.PE1000. CC Bordetella pertussis Tohama I, complete genome. CC complete sequence. CC -!- ANNOTATIONS ORIGIN:Q7VZ03_BORPE CC -!- GENE_FAMILY: HOG000260923 [ FAMILY / ALN / TREE ] DR UniProtKB/Swiss-Prot; Q7VZ03; -. DR EMBL; BX640414; CAE41443.1; -; Genomic_DNA. DR RefSeq; NP_879922.1; NC_002929.2. DR GeneID; 2665391; -. DR GenomeReviews; BX470248_GR; BP1146. DR KEGG; bpe:BP1146; -. DR OMA; IHVADYY; -. DR PhylomeDB; Q7VZ03; -. DR ProtClustDB; CLSK920261; -. DR GO; ...
What is pertussis (whooping cough)? Pertussis (also called whooping cough) is a disease caused by the bacteria Bordetella pertussis that spreads from person-to-person with close contact. It may cause severe coughing fits which can affect breathing. Pertussis is often milder in older children and adults, but can cause serious problems in infants. Pertussis can lead to pneumonia, convulsions, inflammation of the brain and sometimes death. Most of these serious problems occur in infants who are less than one year old. Who can get pertussis? Pertussis can occur in any age group; however, pertussis is more common among infants since they are too young to have full protection from the vaccine. Pertussis is also more common in adolescents and adults who have lost the protection they got from vaccination or illness in childhood. How is pertussis spread? Pertussis is spread from one person to another through respiratory droplets from the nose or throat of an infected person by coughing or sneezing, and ...
Mooi FR; van Loo IHM; van Gent M; He Q; Bart MJ; Heuvelman KJ; de Greeff SC; Diavatopoulos D; Teunis P; Nagelkerke N; Mertsola J (2009 ...
Bordetella pertussis Antibodies, IgA, IgG, & IgM,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories client,medicine,medical supply,medical supplies,medical product
CyaA, the adenylate cyclase toxin from Bordetella pertussis, can deliver its N-terminal catalytic domain into the cytosol of a large number of eukaryotic
Despite the availability of highly effective vaccines, Bordetella pertussis incidence has been rapidly rising in highly vaccinated populations. Recent outbreaks have received media attention, feeding concerns about the emergence of dangerous new strains with increased virulence or that escape vaccine-induced immunity. To accelerate the study of this reemerging pathogen, we sequenced the genomes of 28 B. pertussis strains isolated during outbreaks from 2010 through 2012, making both strains and sequence data available to the scientific community ...
IDENTIFICATION AND USE: a simple chemically defined medium for the production of phase 1 Bordetella Pertussis described consisting of sodium glutamate, proline, cystine, salts, and growth factors, which is suitable for the large-scale production of phase 1 bordetella pertussis. The cultures were detoxified by the addition of 0.14% formalin. The acellular pertussis antigens (PT, FHA, and pertactin) are isolated from Bordetella pertussis culture grown in modified Stainer-Scholte liquid medium. PT and FHA are isolated from the fermentation broth; pertactin is extracted from the cells by heat treatment and flocculation. The antigens are purified in successive chromatographic and precipitation steps. PT is detoxified using glutaraldehyde and formaldehyde. FHA and pertactin are treated with formaldehyde. Each antigen is individually adsorbed onto aluminum hydroxide. Each 0.5-mL dose is formulated to contain 5 Lf of tetanus toxoid, 2.5 Lf of diphtheria toxoid, 8 mcg of inactivated PT, 8 mcg of FHA, and ...
Bordetella pertussis, the human pathogen of whooping cough, when grown at 22 degrees C is nonvirulent and unable to bind eukaryotic cells. In response to a temperature shift to 37 degrees C, the bacterium acquires the ability to bind eukaryotic cells in a time-dependent fashion. By studying in vitro the temperature-induced transition, from the nonvirulent to the virulent state, we found that binding to CHO cells is mediated by the Arg-Gly-Asp-containing domain of filamentous hemagglutinin (FHA), a protein with multiple binding specificities. This protein is synthesized as a 367-kDa polypeptide within 10 min after temperature shift, but requires 2 hr before it is detected on the bacterial cell surface and starts to bind CHO cells. Mutations affecting the cell surface export of FHA abolish bacterial adhesion to CHO cells, while mutations in the outer membrane protein pertactin strongly reduce binding. This suggests that multiple chaperon proteins are required for a correct function of FHA. ...
A mouse immunoglobulin G3 monoclonal antibody specific for the core oligosaccharide moiety of the lipooligosaccharide (LOS) of Bordetella pertussis has been shown to have complement-dependent bactericidal activity. This monoclonal antibody exhibits bactericidal activity against strains of B. pertussis that express the LOS A phenotype. In addition this monoclonal antibody was effective in reducing colonization by B. pertussis in both the lungs and tracheas of mice after aerosol infection. ...
Bordetella pertussis ASR,The B. pertussis ASR contains primers and a FAM-labeled probe that is designed to detect a 103 bp region of the IS481 gene. In addition, the B. pertussis ASR contains primers, a Texas Red-labeled probe and DNA for an internal control sequence. This ASR requires an instrument that can detect FAM and,medicine,medical supply,medical supplies,medical product
Pertussis (whooping cough) is a disease of uncontrollable coughing as a result of infection caused by bacteria Bordetella pertussis Types of food to prevent and treat Pertussis 1. Green tea and black tea In the study to evaluate the efficacy of anti bactericidal activity of tea and catechins against Bordetella pertussis, indicated that pu-erh tea …. ...
Pertussis toxin (PT) is a protein-based AB5-type exotoxin produced by the bacterium Bordetella pertussis, which causes whooping cough. PT is involved in the colonization of the respiratory tract and the establishment of infection. Research suggests PT may have a therapeutic role in treating a number of common human ailments, including hypertension, viral inhibition, and autoimmune inhibition. PT clearly plays a central role in the pathogenesis of pertussis although this was discovered only in the early 1980s. The appearance of pertussis is quite recent, compared with other epidemic infectious diseases. The earliest mention of pertussis, or whooping cough, is of an outbreak in Paris in 1414. This was published in Moultons The Mirror of Health, in 1640. Another epidemic of pertussis took place in Paris in 1578 and was described by a contemporary observer, Guillaume de Baillou. Pertussis was well known throughout Europe by the middle of the 18th century. Jules Bordet and Octave Gengou described in ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Banked acute-phase and convalescent-phase serum samples from a previous study of respiratory illness in university students were examined for significant (≥2-fold) increases in ELISA titers of IgA and IgG antibody to Bordetella pertussis filamentous hemagglutinin, pertactin, and fimbriae-2 and ≥4-fold titer increases to agglutinogens by agglutination. ELISA titers of antibody to pertussis toxin could not be determined because of technical problems. Chlamydia pneumoniae infections were diagnosed by culture or by a ≥4-fold increase in immunofluorescence assay titer or a single high titer (≥512). Mycoplasma pneumoniae, influenza A and B, adenovirus, and respiratory syncytial virus infections were diagnosed by ≥4-fold increases in complement fixation titer or a single high titer (≥64). There were 319 subjects with cough of ≥5 days duration, and of these, 47 (15%) had significant increases in antibody to B. pertussis antigens; 26 (8%) had significant increases to fimbriae-2 or ...
p>The checksum is a form of redundancy check that is calculated from the sequence. It is useful for tracking sequence updates.,/p> ,p>It should be noted that while, in theory, two different sequences could have the same checksum value, the likelihood that this would happen is extremely low.,/p> ,p>However UniProtKB may contain entries with identical sequences in case of multiple genes (paralogs).,/p> ,p>The checksum is computed as the sequence 64-bit Cyclic Redundancy Check value (CRC64) using the generator polynomial: x,sup>64,/sup> + x,sup>4,/sup> + x,sup>3,/sup> + x + 1. The algorithm is described in the ISO 3309 standard. ,/p> ,p class=publication>Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.,br /> ,strong>Cyclic redundancy and other checksums,/strong>,br /> ,a href=http://www.nrbook.com/b/bookcpdf.php>Numerical recipes in C 2nd ed., pp896-902, Cambridge University Press (1993),/a>),/p> Checksum:i ...
Pertussis (Whooping Cough). Pertussis is a highly contagious respiratory disease caused by the bacteria Bordetella pertussis. Pertussis lives in the nose, mouth, and throat of infected individuals. The bacteria are shed in nasopharyngeal secretions and can be spread through coughing, sneezing, or direct contact with fluids from the nose, mouth, or throat of an infected person. If untreated, infected individuals can spread the pertussis bacteria to others from 1 week before cough onset to 21 days after cough onset. Untreated infants (,1 year) remain infectious for up to 42 days from cough onset. When treated with antibiotics, the infectious period is reduced to 5 days after the initiation of treatment. Severe infections can result in complications such as pneumonia among all age groups. Seizures and encephalopathy generally occur only among infants. The average incubation period for pertussis is 7-10 days with a range of 4-21 days.. Case Definition. A cough illness lasting ≥2 weeks with at ...
Escaneado de imágenes de microscopio electrónico de Bordetella pertussis - Gram-negativa, aerobia, no móviles, cocobacilos procariotas (bacterias) que causa la tosferina o pertussis. Sobre la técnica de imagen: Las tecnologías modernas tales como la microscopía electrónica puede dar detalles más finos de las bacterias que la microscopía óptica (luz) e incluso puede ser utilizado para mostrar las características internas. Las micrografías electrónicas son imágenes en blanco y negro generados por los rayos de alta energía de electrones. Las micrografías a veces se les da un color falso para que sean visualmente atractivo (en este caso, se utilizó un tinte verde).. ...
The heterohybridoma cell line HBp2 secreting human monoclonal antibody (hMAb) directed against Bordetella pertussis was generated by fusing SP2/HPT heteromyeloma cells with human spleen lymphocytes, after in vitro stimulation for 6 days. The hybridoma was maintained in culture for more than 1 year w …
False colour transmission electron micrograph of the whooping cough bacterium, Bordetella pertussis. The micrograph shows the bacteriums surface covered in fine hairs called pili or frimbriae. Several types of pili have been identified, based on shape & function. Generally, pili cause bacteria to stick together & attach to foreign cells in the body. The fragments around the bacterium are bits of the growth medium. The whooping cough bacteria parasitise only humans, causing a respiratory tract infection characterised by fits of coughing that end in loud inspiratory whoops. It is potentially fatal in infancy. Magnification: X 20,600 at 35mm size. Original is bw print b220/213. - Stock Image B220/0213
False colour transmission electron micrograph (TEM) of a thin section of the whooping cough bacteria, Bordetella pertussis. The whooping cough bacteria parasitise only humans. They cause a respiratory tract infection characterised by fits of coughing that end in loud inspiratory whoops. The infection is usually contracted in childhood and is potentially fatal in infancy. Adults are sometimes affected. The infection damages the epithelium lining the trachea and bronchi, impairing the beat of the cilia that keep the airways clean. Antibiotics are of very limited effect in treatment. Magnification: X 8800 at 35mm size. - Stock Image B220/0221
ICD-10 A37.00 is whooping cough due to bordetella pertussis without pneumonia (A3700). This code is grouped under diagnosis codes for certain infectious and parasitic diseases.
The Sanger Institute has been funded by the Wellcome Trust to sequence the genomes of Bordetella pertussis strain Tohama I, B. parapertussis strain 12822 and B. bronchiseptica strain RB50 in collaboration with Duncan Maskell and Andrew Preston of the Centre for Veterinary Science, Dept. of Clinical Veterinary medicine, The University of Cambridge. The sequences and analysis are described in: Parkhill et al (2003) Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nature Genetics 35 32-40 (DOI: 10.1038/Ng1227), and have been submitted to EMBL/GenBank with the accession numbers: BX470248 (B. pertussis), BX470249 (B. parapertussis) and BX470250 (B. bronchiseptica). The three sequenced Bordetella strains have been deposited with the ATCC and NCTC under the following accession numbers: Bordetella parapertussis 12822: ATCC BAA-587, NCTC 13253 Bordetella bronchiseptica RB50: ATCC BAA-588, NCTC 13252 Bordetella pertussis Tohama ...
In this study, we have shown that the MLVA is a valuable typing technique to characterize B. pertussis isolates. MLVA is a robust, simple, and portable method which can be used to create strain profiles that are easily electronically exchanged. MLVA has been successfully used to type several different bacterial species and proven to be an excellent method with high resolution, particularly useful for organisms with a low level of sequence diversity (4, 10-12, 16, 18, 19, 27, 28, 31). Although MLVA resulted in high-resolution typing of B. pertussis, the analysis was significantly enhanced after MLVA was combined with sequencing-based analysis of three B. pertussis virulence genes. The latter typing method, designated MAST, also yielded allelic profiles (36). The combined MAST-MLVA profiles were used to perform clustering analyses of the Dutch B. pertussis strains isolated before the introduction of the pertussis vaccine in 1953 and isolates obtained before and after the pertussis epidemics in the ...
Gearing, A.J.; Bird, C.; Wadha, M.; Redhead, K., 1987: The primary and secondary cellular immune responses to whole cell Bordetella pertussis vaccine and its components
The effect of an extract of histamine-sensitizing factor (HSF) of Bordetella pertussis on the immune response of different strains of mice to ovalbumin (OA) was investigated with regard to optimal dose of antigen and adjuvant. It was observed that all strains of mice treated with HSF during immunization with OA demonstrated enhanced production of hemagglutinating antibodies, as compared to animals treated with antigen alone. This enhancement was generally not as great as that demonstrated when Al(OH)3 was the adjuvant. HSF also stimulated a reaginic antibody response (IgE) to OA, but not in all strains of mice. In reagin responders optimal responses were observed with high doses of both antigen and adjuvant, whereas low doses of both produced little or no response. Maximal reagin production occurred usually 14-28 days after immunization and persisted for long periods of time. An anamnestic reagin response was elicited upon secondary immunization with antigen alone, not only in mice immunized ...
Looking for online definition of Bordet-Gengou phenomenon in the Medical Dictionary? Bordet-Gengou phenomenon explanation free. What is Bordet-Gengou phenomenon? Meaning of Bordet-Gengou phenomenon medical term. What does Bordet-Gengou phenomenon mean?
Adenylate cyclase toxin (CyaA) from Bordetella pertussis can subvert host immune responses allowing bacterial colonization. Here we have examined its adjuvant and immunomodulatory properties and the possible contribution of lipopolysaccharide (LPS), known to be present in purified CyaA preparations. CyaA enhanced antigen-specific interleukin-5 (IL-5) and IL-10 production and immunoglobulin G1 antibodies to coadministered antigen in vivo. Antigen-specific CD4+-T-cell clones generated from mice immunized with antigen and CyaA had cytokine profiles characteristic of Th2 or type 1 regulatory T (Tr1) cells. Since innate immune cells direct the induction of T-cell subtypes, we examined the influence of CyaA on activation of dendritic cells (DC) and macrophages. CyaA significantly augmented LPS-induced IL-6 and IL-10 and inhibited LPS-driven tumor necrosis factor alpha and IL-12p70 production from bone marrow-derived DC and macrophages. CyaA also enhanced cell surface expression of CD80, CD86, and ...
Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
FIG 6 Biofilm dispersal by matrix-dissolving agents. Ninety-six-hour biofilms were treated with pronase E in Tris buffer (A), with 40 mM sodium metaperiodate (NaIO4) in H2O (B), and with DNase I in reaction buffer (C) for 2 h at 37°C (filled bars). Biofilms were treated with the respective reaction buffers as controls (open bars). Biofilm reduction is presented as a percentage of the value for the respective strain incubated with buffer only. Average values are shown from one representative assay of three independent replicates, with their respective standard deviations. Significance was assessed by two-way ANOVA. *, P ,0.05; **, P ,0.01; ***, P ,0.001. ...
Since their introduction in the 1940s and 1950s, pertussis vaccines (mostly in combination with diphtheria and tetanus toxoids as diphtheria, tetanus, and pertussis vaccines) have been very efficient in reducing pertussis mortality and morbidity in infants and young children. WHO estimates suggest that between 1999 and 2014, more than 100 000 infant deaths could have been averted mainly by increased coverage of pertussis vaccination.1 Pertussis vaccines come in two varieties: one is made of whole-cell killed Bordetella pertussis cells, consequently called whole-cell pertussis vaccine, and the other is made from one to five purified and partly chemically inactivated bacterial virulence factors, consequently called acellular pertussis vaccine. ...
The adenylate cyclase toxin (AC toxin) is necessary for disease caused by Bordetella pertussis, which has reemerged in the United States over the last two decad...
Despite an increased proportion of Bordetella pertussis isolates lacking pertactin, vaccine effectiveness (VE) is still high in Vermont for the five-dose diphtheria, tetanus, and acellular pertussis vaccine (DTaP) series and the tetanus, diphtheria, and acellular pertussis vaccine (Tdap).
Introduction The routine use of the whole-cell pertussis vaccine has led to a significant reduction in the incidence of the disease in various countries around the world, with a reduction in morbidity and mortality. However, infants up to six months who did not receive the basic vaccination scheme remain susceptible and, when infected by Bordetella pertussis, may present atypical symptoms when compared with older children.1. Over the past few years there have been several reports concerning the severity of pertussis in infants, such as the nine cases reported in the United Kingdom by Smith & Vyas,1 of which six led to death. Severe complications were observed, such as apnea, seizures, respiratory insufficiency, arterial hypotension, pulmonary hypertension, pneumothorax, and secondary bacterial infections.. More recently, another study conducted in the United Kingdom showed that among the 142 infants under five months of age who were hospitalized with a clinical condition of severe respiratory ...
Ca2 Influx and Tyrosine Kinases Trigger Bordetella Adenylate Cyclase Toxin ACT Endocytosis. Cell Physiology and Expression of the CD11b-CD18 Integrin Major Determinants of the Entry Route. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Pertussis, whooping cough, caused by the gram negative pleomorphic bacillus, Bordetella pertussis, is a highly contagious, potentially life-threatening respiratory illness that has re-emerged in the United States (US) as a cause of morbidity and mortality in infants less than 6 months of age as well as morbidity in adolescents and adults. Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) immunization of women in the third trimester of pregnancy represents an opportunity to protect the vulnerable very young infants through passively acquired maternal pertussis specific antibodies. Tdap vaccine is being evaluated for this purpose since there is no monovalent acellular pertussis (aP) vaccine available in the U.S. This is a multi-site, randomized, double masked, cross-over study in 48 healthy pregnant women, 18-45 years of age who will be randomized (2:1) into two groups. One group will receive a single dose of Tdap vaccine at 30-32 weeks of gestation and a ...
HIGASHI, Hisako G. et al. Acellular and low pertussis vaccines: adverse events and the role of mutations. Rev. Inst. Med. trop. S. Paulo [online]. 2009, vol.51, n.3, pp.131-134. ISSN 1678-9946. http://dx.doi.org/10.1590/S0036-46652009000300002.. Objective: to discuss the current PAHO recommendation that does not support the substitution of traditional cellular DTP vaccine by acellular DTP, and the role of mutations, in humans, as the main cause of rare adverse events, such as epileptic-like convulsions, triggered by pertussis vaccine. Data review: the main components related to toxic effects of cellular pertussis vaccines are the lipopolysaccharide of bacterial cell wall and pertussis toxin. The removal of part of lipopolysaccharide layer has allowed the creation of a safer cellular pertussis vaccine, with costs comparable to the traditional cellular vaccine, and which may be a substitute for the acellular vaccine. Conclusion: The new methodology introduced by Instituto Butantan allows for the ...
13) The preventive measure for Bordetella pertussis infection is the vaccination method, the pertussis vaccine is usually administered in combination with toxoids of Diphtheria and tetanus (DTaP). The pertussis vaccine is primarily important for children, preteens, pregnant women, and adults who have never received it, what doses of this vaccine are recommended for children under six years ...
Pertussis, also known as whooping cough, is an extremely contagious respiratory tract infection caused by the bacteria Bordetella pertussis.
Pertussis, or whooping cough, is a highly infectious, nationally notifiable* respiratory disease associated with prolonged cough illness and paroxysms of coughing, inspiratory whoop, or posttussive vomiting. Reported pertussis cases have tripled in the United States since 2001, with 25,616 probable or confirmed cases reported in 2005 (Figure 1). This increase has been attributed to increased circulation of Bordetella pertussis, waning vaccine-induced immunity among adults and adolescents, heightened awareness of pertussis among health-care providers, increased public health reporting, and increased use of polymerase chain reaction (PCR) testing for diagnosis (1). To minimize the spread of pertussis, control measures must be implemented early in the course of illness when the risk for transmission is highest. However, diagnosis of pertussis is complicated by nonspecific signs and symptoms, particularly in the early catarrhal stage of disease. In addition, the lack of rapid, sensitive, and ...
Bordetella pertussis and Bordetella parapertussis are the causal agents of whooping cough in humans. They produce diverse virulence factors, including adenylate cyclase-hemolysin (AC-Hly), a secreted toxin of the repeat in toxins (RTX) family with cyclase, pore-forming, and hemolytic activities. Post-translational modifications (PTMs) are essential for the biological activities of the toxin produced by B. pertussis. In this study, we compared AC-Hly toxins from various clinical isolates of B. pertussis and B. parapertussis, focusing on (i) the genomic sequences of cyaA genes, (ii) the PTMs of partially purified AC-Hly, and (iii) the cytotoxic activity of the various AC-Hly toxins. The genes encoding the AC-Hly toxins of B. pertussis and B. parapertussis displayed very limited polymorphism in each species. Most of the sequence differences between the two species were found in the C-terminal part of the protein. Both toxins harbored PTMs, mostly corresponding to palmitoylations of the lysine 860 residue
Conventional pertussis vaccine prepared from killed whole cell B. pertussis organisms has been in widespread use since the early 1950s. Despite marked reductions in the incidence of pertussis, the use of the vaccine has caused concern because of questions of significant adverse reactions. Whooping cough is not notifiable in South Africa, and there is consequently a paucity of hard data on efficacy; in addition few cases are proven. Incidence, prevalence, severity and transmission of the disease hence remain a matter of conjecture. In order to provide background information and determine baseline data for undertaking further studies, available clinical and epidemiological data on whooping cough (pertussis) in South Africa was collated. It was intended to compare the pattern of disease seen in this country with that known in other parts of the world. Clinical and epidemiological findings from 1525 whooping cough admissions (diagnosed on the basis of clinical criteria) obtained from 6 major ...
PERTUSSIS (WHOOPING COUGH) If your child has had or develops any of the symptoms listed below, please contact your childs medical provider. Pertussis is a vaccine-preventable disease. However, even children who have been immunized against pertussis are susceptible to infection. Pertussis is most severe in the first year of life, particularly for pre-term infants.. School policy excludes children from school until antibiotic treatment has started. In the case of pertussis, 5 days of antibiotic therapy must be completed before the child may return to school. The child should be feeling well and the cough should be manageable prior to return to school. The full course of antibiotics must be completed to prevent relapse. If antibiotics are not given or not completed, the child may be excluded for 21 days from the onset of the cough. A note from the physician may be requested for return to school. CAUSATIVE AGENT: A bacterium, Bordetella pertussis.. SIGNS AND SYMPTOMS: Symptoms usually start with a ...
Pertussis, also known as whooping cough is a serious respiratory illness. It is an infection that often mimics a common cold in the beginning, but can progress quickly, especially in young infants and children. Pertussis is also known as whooping cough. This is because patients often have violent, rapid coughing fits, leaving them to loudly inhale as they try to refill their lungs with air. View more information about Pertussis.. Pertussis is very contagious and spreads rapidly, usually before a patients cough even develops. A vaccine is available against pertussis. Children receive the vaccine in their normal childhood series of Diptheria, Tetanus, Acellular Pertussis (DTAP) shots, but are not fully protected until age five. An adolescent booster is due at age 11 to 12, before a student enters 7th grade. Adults often pass the pertussis infection on to their children, since their immunity has waned from their own childhood immunizations.. A one-time booster of the pertussis vaccine (given in ...
As of July 14, 2015, whooping cough cases in Clark County, Washington have increased eleven-fold, resulting in health officials announcing that outbreak levels have been reached [1]. Thus far in 2015, Clark County has reported 240 cases of whooping cough, leaving the county on track to mirror its whooping cough outbreak of 2012 [2]. In 2012, an estimated 5,000 individuals fell ill to the disease across Washington State, and this years statewide totals have already surpassed 860 cases [2].. About Whooping Cough. Whooping cough, also known as pertussis, is a highly contagious respiratory illness [3]. Caused by the bacteria Bordetella pertussis, the disease is transmitted person-to-person through coughing and sneezing and close contact with others [3]. Infants are at greatest risk of whooping cough infection, as they are unable to receive the vaccine until at least six months old [6].. Whooping cough infection progresses through three stages: catarrhal stage, paroxysmal stage, and convalescent ...
23 August 2016. Taranaki DHB confirmed today that two children aged less than 6 months old have developed whooping cough and a total of 37 people have been notified with the disease in Taranaki, so far this year. Most cases are in older people and the average age being 27 years old.. Dr Jonathan Jarman said, Whooping Cough is a frightening disease, particularly for babies and young children who might go blue or stop breathing during coughing attacks and many need to be hospitalised.. Whooping Cough can be life-threatening as complications are highest in this very young age group. Also, children who are unimmunised are at especially high risk of infection, he added.. Whooping cough (or pertussis) is a highly contagious illness that is caused by a bacterium (Bordetella pertussis). It is spread by an infected person through droplets produced during coughing or sneezing, which is why it is important to keep babies away from people with coughs and to avoid coughing on babies.. Symptoms start with ...
Looking for Bordetella? Find out information about Bordetella. A genus of gram-negative bacteria which are coccobacilli and obligate aerobes, and fail to ferment carbohydrates. These bacteria are respiratory pathogens.... Explanation of Bordetella
Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary ...
Dr Rizwan Uppal, the founder of IDC, believed that proper and timely diagnosis is the key to successful treatment. An all under one roof diagnostic service with the name of Islamabad Diagnostic Center (IDC) Pvt. Ltd was established in the beautiful City of Islamabad more than a decade ago.. This brain child of Dr Rizwan was not possible without the support of his two brothers and Executive directors, Dr Rehan Uppal and Dr Imran Uppal. Since the day of inception, Dr Rehan has been a great assistance and immense help in IDC progress and evolution. IDCs main strength lies in use of state of the art technology, in the hands of qualified and experienced team of doctors and technologist on 24/7 basis. There is still no such setup of equivalent scale and quality in Pakistan.. IDC is one facility where both laboratory and Radiology services. The widest spectrum of in house laboratory tests and imaging investigations are available nowhere, other than at IDC. To further widen the services of rare but ...
Pertussis (whooping cough) is a respiratory tract infection characterized by a paroxysmal cough. The most common causative organism is Bordetella pertussis (see the image below), though Bordetella parapertussis has also been associated with this condition in humans.
The push for family members and young children to rush and get their DTaP shot is certainly unwarranted when one looks at the many well-documented cases of vaccine failure in communities that experienced record numbers of whooping cough cases. In 1996 there was a statewide outbreak of pertussis in Vermont where vaccination rates were among the highest in the country and yet 97 percent of affected children 19-35 months of age had received the recommended number of vaccines. [3] More recently, The Star-Ledger reported on February 11, 2009 of a pertussis outbreak in 21 fully vaccinated children in Hunterdon county, New Jersey.[4] Closer to home, in Toronto, Ontario, from October 2005 to March 2006, a laboratory-confirmed outbreak of pertussis occurred in fully-vaccinated preschool children.[5] Even the British Medical Journal reported on a study revealing that 55 of the 64 children who presented seriological evidence of a recent Bordetella pertussis infection had been fully vaccinated.[6 ...
© 2017 American College of Chest Physicians Background Pertussis (whooping cough) is a highly infective cause of cough that causes significant morbidity and mortality. Existing case definitions include paroxysmal cough, whooping, and posttussive vomiting, but diagnosis can be difficult. We determined the diagnostic accuracy of clinical characteristics of pertussis-associated cough. Methods We systematically searched CINAHL, Embase, Medline, and SCI-EXPANDED/CPCI-S up to June 2016. Eligible studies compared clinical characteristics in those positive and negative for Bordetella pertussis infection, confirmed by laboratory investigations. Two authors independently completed screening, data extraction, and quality and bias assessments. For each characteristic, RevMan was used to produce descriptive forest plots. The bivariate meta-analysis method was used to generate pooled estimates of sensitivity and specificity. Results Of 1,969 identified papers, 53 were included. Forty-one clinical characteristics
BACKGROUND: Few data exist describing pertussis epidemiology among infants and children in low- and middle-income countries to guide preventive strategies. METHODS: Children 1-59 months of age hospitalized with World Health Organization-defined severe or very severe pneumonia in 7 African and Asian countries and similarly aged community controls were enrolled in the Pneumonia Etiology Research for Child Health study. They underwent a standardized clinical evaluation and provided nasopharyngeal and oropharyngeal swabs and induced sputum (cases only) for Bordetella pertussis polymerase chain reaction. Risk factors and pertussis-associated clinical findings were identified. RESULTS: Bordetella pertussis was detected in 53 of 4200 (1.3%) cases and 11 of 5196 (0.2%) controls. In the age stratum 1-5 months, 40 (2.3% of 1721) cases were positive, all from African sites, as were 8 (0.5% of 1617) controls. Pertussis-positive African cases 1-5 months old, compared to controls, were more often human
In addition, if the trends continue through the end of this year, which they are likely to do, this will be the highest incidence of pertussis in almost 50 years. These numbers are not in question, but there is some discussion about what, exactly, is causing it.. The tempting conclusion is that pertussis is making its way back into the population due largely to vaccine refusal and anti-vaccine propaganda. However, there is yet no data to support that conclusion. It may or may not be the case - we will know once a more thorough analysis is done of the individual cases of pertussis. And in any case, there are many factors at work.. First, pertussis has a natural tendency to cycle every 5 years or so, and this year is the peak of the cycle. This is certainly a significant part of the increase this year, regardless of other contributors.. In addition, the lack of vaccine-induced immunity is also playing a role, but not necessarily from vaccine refusal. Pertussis is a very contagious illness, partly ...
Bordetella Vaccines - Bordetella vaccines will ensure your pet doesnt come down with kennel cough. Learn more about bordetella vaccines and treatments.
Definition of Bordet-Gengou phenomenon. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
Atack JM, Srikhanta YN, Fox KL, Jurcisek JA, Clark TA, Boitano M, Power PM, Jen FE-C, McEwan AG, Grimmond SM, Smith AL, Barenkamp SJ, Korlach J, Bakaletz LO, Jennings MP. A biphasic epigenetic switch controls immunoevasion, virulence and niche adaptation in nontypeable Haemophilus influenzae. Nat Commun. (January 0.): -.. Ompremcak LB, Rheins MS.. Scanning electron microscopy of mouse ciliated oviduct and tracheal epithelium infected in vitro with Bordetella pertussis. Can J Microbiol. Vol. 29, (January 1982.): 415-420.. Bakaletz LO, Rheins MS.. A whole-organ perfusion model of Bordetella pertussis adherence to mouse tracheal epithelium. In Vitro Cell Dev Biol. Vol. 21, no. 6. (January 1985.): 314-320.. Bakaletz LO, DeMaria TF, Lim DJ.. Effect of preopsonization on phagocytosis of Haemophilus influenzae. Arch Otolaryngol. Vol. 113, no. 5. (January 1987.): 526-529.. Lim DJ, DeMaria TF, Bakaletz LO.. Functional morphology of the tubotympanum related to otitis media: a review. Am J Otol. ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
기관지염(氣管支炎, bronchitis)은 폐의 기관지에 생기는 염증이다.[1] 증상으로는 가래, 천명, 호흡 곤란, 가슴의 불편함 등이 있다.[1] 기관지염은 급성 및 만성 두 종류로 분류된다.[1] 급성 기관지염은 기침 감기로도 알려져 있다.[1] 급성 기관지염은 보통 3 주 정도 지속적으로 기침을 한다.[2] 원인의 90 % 이상이 바이러스 감염이다.[2] 이 바이러스는 기침을 통해, 혹은 직접적인 접촉을 통해 공중에 퍼질 수 있다.[1] 흡연, 먼지 및 기타 대기 오염에 대한 노출이 위험 요인이다.[1] 폐렴미코플라스마(Mycoplasma pneumoniae) 나 백일해균(Bordetella pertussis)과 같은 박테리아나 고농도의 대기 오염에 의한 경우도 소량 존재한다.[2][3]급성 기관지염의 치료에는 일반적으로 휴식, paracetamol (acetaminophen) 및 NSAIDs가 발열에 도움이 된다.[4][5] 만성 기관지염은 적어도 2 년 동안, 1 년에 3 ...
Adequately sensitive and specific methods to diagnose pertussis in adolescents and adults are not widely available. Currently, no Food and Drug Administration approved diagnostic assays are available for the serodiagnosis of Bordetella pertussis. Since concentrations of B. pertussis-specific antibodies tend to be high during the later-phases of disease, a simple, rapid, easily transferable serodiagnostic test was developed. This paper describes test development, initial evaluation of a prototype kit enzyme-linked immunosorbent assay (ELISA) in an inter-laboratory collaborative study, and the analytical validation. The data presented here demonstrate that the kit met all pre-specified criteria for precision, linearity, and accuracy for samples with anti-pertussis toxin (PT) immunoglobulin G (IgG) antibody concentrations in the range of 50 to 150 ELISA units (EU)/mL, the range believed to be most relevant for serodiagnosis. The assay met the precision and linearity criteria for a wider range, ...
Grandmother is portrayed as the big bad wolf in a whooping cough vaccine PSA.,br /, ,br /, A killer infectious disease called Pertussis is a bacterial infection that causes whooping cough. Vaccines had brought the numbers of cases down dramatically, but now theyre on the rise again and Texas Biomed animals and scientists are involved in the search for something better to treat this health problem that kills more than a hundred thousand infants a year.,br /, ,br /, Pertussis has seen an alarming resurgence in the last decade. Thats surprising, given that a vaccine for this infectious disease has existed since the 1930s. The original vaccine, made with whole-cell killed Bordetella pertussis bacteria, was very effective but associated with some adverse events. A newer acellular pertussis vaccine with fewer adverse events was approved by the FDA in 1997. Recent epidemiological studies have found, however, that the immunity conferred by the new vaccine wears out during adolescence. Thats a ...
The abilities of cysteine-containing compounds to support growth of and influence pertussis toxin transcription, assembly, and secretion were examined. source of cysteine; however, in the absence of reduced glutathione, pertussis toxin was not efficiently secreted. Addition of the reducing agent dithiothreitol was unable to compensate for the lack of reduced glutathione and did not promote secretion of pertussis toxin. These results suggest that reduced glutathione does not affect the accumulation of assembled active pertussis toxin in the periplasm but plays a role in efficient pertussis toxin secretion by the bacterium. Pertussis toxin is a major virulence factor of heat-labile toxin, and Shiga toxin. Pertussis toxin has the most complex structure of any bacterial toxin (18, 20, 24). It is assembled from six subunits encoded by five genes, to encodes the structural gene for the A-subunit, which is an ADP-ribosyltransferase. S1 modifies mammalian G-proteins, which play a critical role in ...
Before Canadas public pertussis vaccine program, incidence of the disease averaged 156 cases per 100 000 people. In contrast, with a vaccination program, the number of new cases ranged from 2 per 100 000 in 2011 to 13.9 in 2012. Most cases are in under-immunized populations. The current whooping cough vaccine (an acellular vaccine) has been used in Canada since 1997 and is also used in the rest of North America, Australia, New Zealand and much of Europe. The whole-cell vaccine was discontinued in North America because of adverse reactions in children, which included soreness at the injection site and fevers. The current study analyzed public health laboratory data linked with population-level vaccination data for a total of 5867 people born between 1992 and 2013, with 486 individuals testing positive for pertussis and the remaining 5381 testing negative. The researchers found that immunity was high during the first three years after vaccination but there was little protection after seven ...
Previous research in several countries has shown that Bordetella pertussis (whooping cough) infection is an endemic disease among adolescents and adults. Data also shows that neither infection nor immunisation results in lifelong immunity. Yet general practitioners in the UK seldom diagnose or even consider pertussis in older children. It is perceived as a disease of very young children who have not been immunised and who have classic features such as whoop ...
As a pediatric infectious disease specialist, I find it troubling that this study may be used as an excuse not to vaccinate parents and other contacts of young infants. First, the findings do not necessarily apply to areas experiencing high rates of pertussis outbreaks. The report also does not consider communities with a large Hispanic population. When compared with other ethnicities in the United States, Hispanic infants are known to have higher rates of infection and death from pertussis. This is a critical point when looking at a state like Texas, where nearly 40 percent of the population is Hispanic. Since 2000, 34 Texas babies have died from pertussis. The Centers for Disease Control and Prevention recognize that cocooning is needed because even if infants receive antibodies from their mother, these antibodies fade away before the infant has had three doses of pertussis vaccine, given at 2, 4, and 6 months of age. Cocooning is also needed to protect infants born prematurely before the ...
LUBBOCK, TX (KCBD) - The City of Lubbock Health Department would like to notify citizens and clinicians of an increase in Pertussis cases this spring. There have been 22 reported cases in Lubbock County so far in 2010. There were 29 total reported cases of Pertussis in 2009.. Pertussis cases generally increase in the spring and fall months. Pertussis, which is also known as Whooping Cough, is spread by infected persons coughing or sneezing while in close contact with others, who then breathe in the Pertussis bacteria. Many infants who get pertussis are infected by older siblings or parents who might not even know they have the disease.. Pertussis can cause serious illness in children and adults. The disease starts like the common cold, with runny nose or congestion, sneezing, and sometimes mild cough or fever. The cough worsens, becoming severe after 1-2 weeks. Children with the disease cough violently and rapidly, over and over, until the air is gone from their lungs and theyre forced to ...
The Department of Public Health and Social Services (DPHSS) received a laboratory confirmed case of Pertussis (whooping cough) in a 7-month-old child. Epidemiologic investigation of the case to determine possible source of exposure has been initiated.. Pertussis is a highly contagious bacterial disease of the respiratory tract caused by Bordetella Pertussis. Unimmunized or incompletely immunized young infants are particularly vulnerable. It is primarily spread by direct contact with discharge from the nose and throat of infected individuals. It is essential that children receive all their vaccinations on time to prevent this disease.. The DPHSS continues to encourage parents to protect their infants and young children by minimizing exposure (close contact) to persons who have cold symptoms or cough illness. In addition, it is essential that children receive all their shots on time to prevent and control this disease. All physicians are advised to routinely check the immunization status of their ...
Whooping Cough is an acute infection of the respiratory tract, seen only in children. It is typically a prolonged illness with an average duration of 6-8 weeks. The incubation period is 7-10 days. Anyone can get whooping cough, but the health effects are usually much worse for children less than a year old. In Canada, whooping cough now kills one to three infants per year, usually those who are unvaccinated, or under-vaccinated. With proper care, most teenagers and adults recover from whooping cough without complications. Whooping cough is more serious in children, especially infants younger than 6 months of age. Whooping cough - known medically as pertussis -is a highly contagious respiratory tract infection. Pertussis, also called whooping cough, is caused by Bordetella pertussis bacteria and is extremely contagious. Before a vaccine was available, pertussis killed 5,000 to 10,000 people in the United States each year. In the more advanced stages, its marked by the symptom that gives the ...
In the last week, we have seen a couple of little ones show up with confirmed cases of whooping cough.. Whooping cough, or pertussis, is an infection of the respiratory tract caused by the bordetella pertussis bacteria. It starts out looking like the common cold-runny nose, fever, mild cough. This is then followed by severe coughing fits, sometimes with the characteristic whoop sound at the end of the fit. These coughing fits can go on for 10 weeks, giving it the nickname the 100-day cough.. You can hear the sounds of pertussis here.. But…I thought we had vaccines for pertussis?. Whooping cough is actually the second most common infectious childhood disease in Canada, after influenza. Its endemic, meaning its always around, but it usually doesnt show itself much-just in minor periodic outbreaks.. This isnt unusual-the vaccine isnt perfect. Its estimated to have about an 80-85% effectiveness after three doses, and that effectiveness wears off over time. As a result, whooping cough ...
Pertussis (Whooping cough) Bordetella pertussis Plague Yersinia pestis Pneumococcal infection Streptococcus pneumoniae ...
Bordetella pertussis 1. She was a full professor of biomedicine at Mucosal Immunology and Vaccine Center in Gothenburg. ...
... is an adenylate cyclase produced by Bordetella pertussis. Kessin RH, Franke J (April 1986). " ... Ladant D, Brezin C, Alonso JM, Crenon I, Guiso N (December 1986). "Bordetella pertussis adenylate cyclase. Purification, ... "Secreted adenylate cyclase of Bordetella pertussis: calmodulin requirements and partial purification of two forms". J. ...
In Bordetella pertussis, the infectious agent in childhood whooping cough, filamentous haemagglutinin (FHA) is a surface- ... "Filamentous hemagglutinin of Bordetella pertussis. A bacterial adhesin formed as a 50-nm monomeric rigid rod based on a 19- ... "Beta-helix model for the filamentous haemagglutinin adhesin of Bordetella pertussis and related bacterial secretory proteins". ... Inatsuka CS, Julio SM, Cotter PA (December 2005). "Bordetella filamentous hemagglutinin plays a critical role in ...
Diseases such as pertussis (or whooping cough) are caused by the bacteria Bordetella pertussis. This bacteria is marked by a ... Yeh, Sylvia H.; Mink, ChrisAnna M. (2012). "Bordetella pertussis and Pertussis (Whooping Cough)". Netter's Infectious Diseases ... The pertussis toxin is a protein exotoxin that binds to cell receptors by two dimers and reacts with different cell types such ... PCR is an important testing tool that can detect sequences within the gene for the pertussis toxin. Because PCR has a high ...
2003). "Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella ... and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies". Clinical ... 1991). "Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro". Infection and Immunity ... Luker, K. E.; Collier, J. L.; Kolodziej, E. W.; Marshall, G. R.; Goldman, W. E. (1993). "Bordetella pertussis Tracheal ...
Corynebacterium diphtheriae and Bordetella pertussis. ubiquitination and SUMOylation Various full-length, folded proteins can ...
Pertussis is caused by the bacterium Bordetella pertussis. It is spread easily through the coughs and sneezes of an infected ... Pertussis is caused by the bacterium Bordetella pertussis. It is an airborne disease (through droplets) that spreads easily ... Pertussis infection in these persons may be asymptomatic, or present as illness ranging from a mild cough to classic pertussis ... The pertussis vaccine became available in the 1940s. Play media The classic symptoms of pertussis are a paroxysmal cough, ...
Pertussis toxin is secreted by the gram-negative bacterium, Bordetella pertussis. Whooping cough is very contagious and cases ... Guiso N. 2009.Bordetella pertussis and pertussis vaccines. Clin. Infect. Dis. 49:1565-1569 Faruque, S. M.; Chowdhury, N; Khan, ... Carbonetti, N. H. (2010). "Pertussis toxin and adenylate cyclase toxin: Key virulence factors of Bordetella pertussis and cell ... The bacterium Bordetella pertussis was first identified as the cause of whooping cough and isolated by Jules Bordet and Octave ...
With Jules Bordet he isolated Bordetella pertussis in pure culture in 1906 and declared it as the cause of whooping cough. In ... He researched with Jules Bordet the Bordetella pertussis bacteria. At the age of 22, he obtained his doctorate at the ... The pertussis endotoxin. Etiologie de la coqueluche. Etat actuel de la question, 1909 - Etiology of pertussis. Current status ... Le Microbe de la coqueluche, 1906 - The microbe "pertussis". Note complémentaire sur le microbe de la coqueluche, 1906 - ...
... is a highly immunogenic virulence factor of Bordetella pertussis, the bacterium that causes pertussis. Specifically, it is an ... PRN is purified from Bordetella pertussis and is used for the vaccine production as one of the important components of ... Emsley, P.; Charles, I. G.; Fairweather, N. F.; Isaacs, N. W. (1996). "Structure of Bordetella pertussis virulence factor P.69 ... Emsley P, Charles IG, Fairweather NF, Isaacs NW (May 1996). "Structure of Bordetella pertussis virulence factor P.69 pertactin ...
Bordetella pertussis. Bordetella bronchiseptica and Bordetella parapertussis, also able to cause pertussis-like symptoms, also ... Vaccination against Bordetella pertussis is used in infancy to prevent whooping cough. The recent switch from whole-cell ... Adenylate cyclase toxin is a virulence factor produced by some members of the genus Bordetella. Together with the pertussis ... Adenylate cyclase toxin from Bordetella pertussis is a 1706 amino acid residue long protein. The protein consists of three ...
"Vaccine Development for the Control of Bordetella Pertussis Infections". Infection and Immunity. 86 (6): e00004-18. doi:10.1128 ...
"Interaction of human Tamm-Horsfall glycoprotein with Bordetella pertussis toxin". Microbiology. 148 (Pt 4): 1193-1201. doi: ...
Bordetella pertussis, Haemophilus influenzae), and some respiratory tract and soft-tissue infections. The antimicrobial ... "Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study". Lancet ...
Bordetella pertussis is a Gram-negative coccobacillus responsible for causing whooping cough. Yersinia pestis, the bacteria ...
"Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the ... "The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18)". J. ... "Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin". EMBO J. 24 (18): 3190-201 ... Pertussis toxin Anthrax toxin PDB: 2COL​; Guo Q, Shen Y, Lee YS, Gibbs CS, Mrksich M, Tang WJ (September 2005). " ...
Gordon's work focused on pertussis cultures and virulence of the bacterium Bordetella pertussis. Gordon's analysis of pertussis ... Kendrick to support pertussis research at the Michigan Department of Health's Grand Rapids lab around 1944. In the early 1940s ... and the Grand Rapids Pertussis Trials, 1932-1939". Michigan Historical Review. 33 (1): 59-85. JSTOR 20174193. "Journal No. 62 ... doctors Pearl Kendrick and Grace Eldering with bacteriological virulence research leading to the creation of the pertussis ...
Bordetella pertussis) 2014 Case Definition. Centers for Disease Control and Prevention. Retrieved December 16, 2015. CS1 maint ... CS1 maint: discouraged parameter (link) "CSTE Position Statement 13-ID-15". CDC (NNDSS) Diseases and Conditions - Pertussis / ...
Skerry C, Goldman WE, Carbonetti NH (February 2019). "Bordetella pertussis and Contributes to Sphingosine-1-Phosphate Receptor ... pneumonia associated with impaired bacterial clearance and more severe pulmonary inflammation following Bordetella pertussis ...
These adenylyl cyclases are toxins secreted by pathogenic bacteria such as Bacillus anthracis, Bordetella pertussis, ... "Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin". The EMBO Journal. 24 (18 ...
Pertussis is caused by the bacterium Bordetella pertussis.[4] It is an airborne disease which spreads easily through the coughs ... Pertussis is caused by the bacterium Bordetella pertussis. It is an airborne disease (through droplets) that spreads easily ... and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies". Clin ... Ebell, MH; Marchello, C; Callahan, M (2017). "Clinical Diagnosis of Bordetella Pertussis Infection: A Systematic Review". J Am ...
"Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica". ...
Schnoeller, C; Roux, X; Sawant, D; Raze, D; Olszewska, W; Locht, C; Openshaw, PJ (2013). "Attenuated Bordetella Pertussis ...
The C-terminal domain of the adenylate cyclase toxin (ACT or CyaA; TC# 1.C.11.1.4) of Bordetella pertussis forms a small cation ... Adenylate cyclase toxin (ACT or CyaA), is a primary virulence factor in Bordetella pertussis. CyaA is a multifunctional RTX ... "Membrane restructuring by Bordetella pertussis adenylate cyclase toxin, a member of the RTX toxin family". Journal of ... "The Adenylate Cyclase Toxin of Bordetella pertussis Binds to Target Cells via the αMβ2 Integrin (Cd11b/Cd18)". Journal of ...
"Mannose receptor and macrophage galactose-type lectin are involved in Bordetella pertussis mast cell interaction". Journal of ...
Because pertussis is known to be caused by the bacterium Bordetella pertussis, vaccination is effective. A paper co-authored in ... July 2018). "Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in ... "Pertussis (Whooping Cough)". Centers for Disease Control and Prevention. Retrieved 20 November 2020. Chisholm, Hannah; Howe, ... In 1916 Petousis-Harris and a team of researchers evaluated whether the switch from whole cell to acellular pertussis vaccine ...
2003). "Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella ... and Bordetella. Achtman was one of the inventors of multilocus sequence typing. His research has been funded by the ...
Bordetella pertussis, the causative bacterium of whooping cough, secretes its pertussis toxin partly through T4SS. Legionella ...
Bordetella pertussis, Fusobacterium sp., Corynebacterium diphtheriae, Treponema pallidum, and Neisseria gonorrhoeae. Anaerobic ...
Tako kot Bordetella pertussis tudi ta vrsta tvori od kalmodulina odvisni adenilat-ciklazni eksotoksin, imenovan edemski faktor ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
gadā (Bordetella pertussis jeb Bordē-Žangū baktērija).[9] Slimības ierosinātājs ir Bordetella pertussis, nekustīga gramnegatīva ... Infant Pertussis Study Group. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J., 2007 Apr;26(4):293- ... 21,0 21,1 21,2 ECDC Guidance and protocol for the serological diagnosis of human infection with Bordetella pertussis. 2012 Oct; ... Polymorphism of Bordetella pertussis Isolates Circulating for the Last 10 Years in France, Where a Single Effective Whole-Cell ...
Bordetella pertussis. *Bradyrhizobium japonicum. *Burkholderia gladioli. C. *Campylobacter. *Campylobacterales. *Chlamydia ( ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
Bordetella pertussis, the causative agent of whooping cough, secretes the pertussis toxin partly through the type IV system. ...
... small number of cases are due to high levels of air pollution or bacteria such as Mycoplasma pneumoniae or Bordetella pertussis ... small number of cases are due to high levels of air pollution or bacteria such as Mycoplasma pneumoniae or Bordetella pertussis ... An exception is when acute bronchitis is due to pertussis. Tentative evidence supports honey and pelargonium to help with ...
Burkholderia pseudomallei (Melioidosis) · Burkholderia mallei (Glanders) · Burkholderia cepacia complex · Bordetella pertussis/ ...
백일해(百日咳; 문화어: 백날기침; 영어: pertussis)는 전염성이 매우 높은 세균병이다.[1][2][3][4] 백일해균(학명: Bordetella pertussis)으로 일어나는 어린이의 호흡기 전염병으로서, 한번 걸리면 ... Top KA, Halperin SA (2017). 》Pertussis and other Bordetella infections》. Kasper DL, Fauci AS. 》Harrison's Infectious Diseases》 ... Carbonetti NH (June 2007). "Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease". 》Curr Opin ... Carbonetti NH (June 2007). "Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease". 》Current ...
Bordetella pertussis. Whooping cough. DPT vaccine. Boostrix, Adacel, Daptacel, Infanrix, Tripedia, Kinrix, Pediarix, Pentacel, ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
Je to jedna z mála známych baktérií, ktorá dokáže syntetizovať proteínovú kapsulu, Podobne ako Bordetella pertussis, formuje ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX-). Lac+. *Klebsiella pneumoniae * ...
വില്ലൻചുമയെ പ്രതിരോധിക്കുന്ന വാക്സിൻ ആണ് പെർട്ടുസ്സിസ് വാക്സിൻ(Pertussis vaccine).[1] ഇവ പ്രധാനമായും രണ്ടുതരത്തിലാണുള്ളത്: മുഴു ... Bordetella pertussis. Type. ?. Clinical data. MedlinePlus. a682198. Legal status. Legal status. *℞ (Prescription only) ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
Corynebacterium diphtheriae and Bordetella pertussis.. *ubiquitination and SUMOylation. Various full-length, folded proteins ...
... as well as Bordetella pertussis which causes whooping cough. Other members of the class can infect plants, such as Burkholderia ...
Diseases such as pertussis (or whooping cough) are cause by the bacteria Bordetella pertussis. This bacteria is marked by a ... The pertussis toxin is a protein exotoxin that binds to cell receptors by two dimers and reacts with different cell types such ... PCR is very efficient for diagnosing pertussis when compared to culture.[34] ... PCR is an important testing tool that can detect the sequences that are within the pertussis toxin gene. This is because PCR ...
Pertussis toxin (PTx) of Bordetella pertussis, formerly known as lymphocytosis-promoting factor, causes a decrease in the entry ...
Seperti Bordetella pertussis, ia membentuk eksotoksin adenilat siklase yang bergantung pada kalmodulin yang dikenal sebagai ...
Burkholderia pseudomallei (Melioidosis) · Burkholderia mallei (Glanders) · Burkholderia cepacia complex · Bordetella pertussis/ ...
Bordetella pertussis/Bordetella parapertussis *Pertussis. γ. Enterobacteriales. (OX−). Lac+. *Klebsiella pneumoniae * ...
The 'a' in DTaP and Tdap stands for 'acellular,' meaning that the pertussis component contains only a part of the pertussis ... such as Bordetella bronchiseptica, has likely increased in recent years.[104] In some cases, most notably rabies, the parallel ... toxoids and pertussis (P) vaccine. Lower-case "d" and "p" denote reduced doses of diphtheria and pertussis used in the ... In the preparation for the 1990 Persian Gulf campaign, whole cell pertussis vaccine was used as an adjuvant for anthrax vaccine ...
위험 요인으로는 흡연, 먼지 및 기타 대기 오염에 대한 노출이 포함된다.[1] 폐렴미코플라스마(Mycoplasma pneumoniae) 나 백일해균(Bordetella pertussis)과 같은 박테리아나 고농도의 대기 오염에 ... Bordetella pertussis)과 같은 박테리아나 고농도의 대기 오염에 의한 경우도 소량 존재한다.[2][3]급성 기관지염의 치료에는 일반적으로 휴식, paracetamol (acetaminophen) 및 NSAIDs가 ...
Definition of Bordetella pertussis. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and ... Bordetella pertussis. Definition: the bacterial species that is the causative agent of whooping cough, a respiratory tract ... is associated with production of pertussis toxin, a protein consisting of 5 B. subunits that bind the molecule to respiratory ...
In addition, the B. pertussis ASR contains primers, a Texas Red-labeled probe and DNA for an internal control sequence. This ... pertussis ASR contains primers and a FAM-labeled probe that is designed to detect a 103 bp region of the IS481 gene. ... Bordetella pertussis Antibody, IgM. 5. Bordetella pertussis Antibody, IgG. 6. Bordetella pertussis by PCR. 7. Bordetella ... Bordetella pertussis DFA. 10. Bordetella pertussis Toxin Antibody, IgA. 11. Bordetella pertussis Toxin Antibody, IgG. ...
16: Pertussis Parkhill J, et al. (2003). "Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella ... Nieves DJ, Heininger U (2016). "Bordetella pertussis". Bordetella pertussis. Microbiology Spectrum. 4. pp. 311-339. doi:10.1128 ... Bordetella pertussis is a Gram-negative, aerobic, pathogenic, encapsulated coccobacillus of the genus Bordetella, and the ... "Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence". Infection, Genetics and Evolution. 40: ...
Bordetella pertussis pathogenesis: current and future challenges.. Melvin JA1, Scheller EV1, Miller JF2, Cotter PA1. ... a) Pertussis toxin (PT, PDB ID 1PRT), is an AB5-type toxin composed of one catalytic subunit (A subunit) and five membrane- ... b) Bordetella spp. fimbriae are type 1 pili. FimB is similar to chaperone proteins that traffic major fimbrial subunits (Fim2 ... c) Bordetella spp. adenylate cyclase toxin (ACT) is composed of two primary domains, a calmodulin-responsive adenylate cyclase ...
... , Whooping Cough Test, Pertussis Diagnostics, Pertussis Culture, Pertussis PCR, Bordatella PCR. ... Bordetella Pertussis Test. Bordetella Pertussis Test Aka: Bordetella Pertussis Test, Whooping Cough Test, Pertussis Diagnostics ... Bordetella Pertussis Test Colorimetric Capnometry Delta F508 Diffusing Capacity End-Tidal CO2 End-Tidal O2 Exercise Spirometry ... These images are a random sampling from a Bing search on the term "Bordetella Pertussis Test." Click on the image (or right ...
Bordetella pertussis synonyms, Bordetella pertussis pronunciation, Bordetella pertussis translation, English dictionary ... definition of Bordetella pertussis. n. 1. A part that forms the outer edge of something. 2. A decorative strip around the edge ... Bordetella pertussis - definition of Bordetella pertussis by The Free Dictionary https://www.thefreedictionary.com/Bordetella+ ... Bordetella pertussis infections maybe a common cause of persistent cough in adults, said Dr.. B. Pertussis, Chronic Cough ...
... ,ARUP Laboratories is a national reference laboratory and a worldwide leader in ... Bordetella pertussis Antibody, IgM. 5. Bordetella pertussis Antibody, IgG. 6. Bordetella pertussis by PCR. 7. Bordetella ... Bordetella pertussis ASR. 2. Bordetella pertussis Antibodies, IgA & IgG. 3. Bordetella pertussis Antibodies, IgG & IgM. 4. ... Bordetella pertussis DFA. 10. Bordetella pertussis Toxin Antibody, IgA. 11. Bordetella pertussis Toxin Antibody, IgG. ...
Inhibition of murine allergic airway disease by Bordetella pertussis.. Kim YS1, Kwon KS, Kim DK, Choi IW, Lee HK. ... pertussis (2 × 109 cells) and (b) Varying doses of B. pertussis DNA were administered i.p. 1 day before the first airway ... Ten µg of DNA was mixed with 10 U of CpG methylase for 16 hr or DNase I for 2 hr at 37°. One µg of B. pertussis DNA were ... P , 0·01 versus control **P , 0·05 versus B. pertussis DNA-treated group. (e) PT, LPS, and FHA were inactivated as described in ...
Pertussis: Not Your Typical URI By Brit Long, MD & Alex Koyfman, MD ...
Comparative genomics of the classical Bordetella subspecies: the evolution and exchange of virulence-associated diversity ...
... tracto respiratorio que se presenta exclusivamente en los seres humanos y es causada por la bacteria gramnegativa Bordetella ... Bordetella Pertussis: Tos Ferina. La tos ferina es una enfermedad del tracto respiratorio que se presenta exclusivamente en los ... Bordetella pertussis. Contienen fimbrias, pilis y cápsula. Son aerobios estrictos. Citotoxina traqueal produce cilio-estasis. ... Transcript of Bordetella Pertussis: Tos Ferina. Son microorganismos cocobacilares gramnegativos.. Patogenia. Factores que ...
However, a significant prevalence of Prn-deficient (Prn−) B. pertussis was observed in Japan. The Prn− isolate was first ... discovered in 1997, and 33 (27%) Prn− isolates were identified among 121 B. pertussis isolates collected from 1990 to 2009. ... is one of the major virulence factors of Bordetella pertussis, the etiological agent of whooping cough. ... Bordetella pertussis Is the Subject Area "Bordetella pertussis" applicable to this article? Yes. No. ...
Helical structure of Bordetella pertussis fimbriae.. A C Steven, M E Bisher, B L Trus, D Thomas, J M Zhang, J L Cowell ... Helical structure of Bordetella pertussis fimbriae. Message Subject (Your Name) has forwarded a page to you from Journal of ... The helical structures of Bordetella pertussis fimbriae of serotypes 2 and 6 were determined by optical diffraction analysis of ...
... industrial applications and more information for Bordetella pertussis. ... Bordetella pertussis is BSL2 organism and should be considered a potential pathogen.. ... Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales; Alcaligenaceae; Bordetella. Industrial uses or economic ...
Immunization with agglutinogen 2 protected mice against infection with 1.2.0 or 1.2.3 serotypes of B. pertussis, whereas ... The ability of purified serospecific agglutinogens from Bordetella pertussis to protect mice against intranasal infection has ... Serospecific protection of mice against intranasal infection with Bordetella pertussis Vaccine. 1989 Aug;7(4):321-4. doi: ... The ability of purified serospecific agglutinogens from Bordetella pertussis to protect mice against intranasal infection has ...
Genomic DNA from Bordetella pertussis Strain Tohama 1 TypeStrain=False Application: ... Bordetella pertussis (Bergey et al.) Moreno-Lopez (ATCC® BAA-589D-5™) Strain Designations: Genomic DNA from Bordetella ... Bordetella pertussis (Bergey et al.) Moreno-Lopez ATCC® BAA-589D-5™ dried At least 5 µg in 1X TE buffer. OD260/OD280: 1.6 to ... Quantitative Genomic DNA from Bordetella pertussis (ATCC® BAA-589DQ™) Add to frozen Specification range: ≥ 1 x 105 copies/µL. ...
NAME: Bordetella pertussis. SYNONYM OR CROSS REFERENCE: Originally named Haemophilus pertussis F Footnote 1, Whooping cough ... CHARACTERISTICS: Bordetella pertussis are small, gram-negative, encapsulated, non-motile, coccobacilli with outer pili. They ... Pathogen Safety Data Sheets: Infectious Substances - Bordetella pertussis. PATHOGEN SAFETY DATA SHEET - INFECTIOUS SUBSTANCES. ... Wilson, K. E., Cassiday, P. K., Popovic, T., & Sanden, G. N. (2002). Bordetella pertussis isolates with a heterogeneous ...
Abcam provides general protocols for Human Anti-Bordetella pertussis IgA ELISA Kit (ab108708). Please download our pdf protocol ...
Human Bordetella pertussis IgG ELISA Kit is a sensitive immunoassay suitable for the quantification of Bordetella pertussis IgG ... Bordetella pertussis anti-IgG HRP Conjugate. Black cap. 1 x 20ml. Bordetella pertussis IgG Cut-off Control. Green cap. 1 x 3ml ... Human Anti-Bordetella pertussis IgG ELISA Kit. See all Bordetella pertussis IgG kits. ... ELISA - Human Anti-Bordetella pertussis IgG ELISA Kit (ab108709) Protein - Native Human IgG FC fragment protein (ab90285) SDS- ...
Discover a faster, simpler path to publishing in a high-quality journal. PLOS ONE promises fair, rigorous peer review, broad scope, and wide readership - a perfect fit for your research every time. Learn More Submit Now ...
Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. ... Differential regulation of type III secretion and virulence genes in Bordetella pertussis and Bordetella bronchiseptica by a ... The BvgAS Regulon of Bordetella pertussis. Kyung Moon, Richard P. Bonocora, David D. Kim, Qing Chen, Joseph T. Wade, Scott ... The BvgAS Regulon of Bordetella pertussis. Kyung Moon, Richard P. Bonocora, David D. Kim, Qing Chen, Joseph T. Wade, Scott ...
Bordetella pertussis. The whooping cough bacteria parasitise only humans. They cause a respiratory tract infection ... Keywords: bacteria, bacterial, bacteriology, bacterium, betaproteobacteria, bordetella pertussis, electron micrograph, infect, ... Bordetella pertussis. The whooping cough bacteria parasitise only humans. They cause a respiratory tract infection ...
Viable cell numbers (cfu/ml) of the B. pertussis strains and a rough strain of B. bronchiseptica (CSU-P-1) d … ... pertussis and one strain of B. parapertussis exposed to hyperimmune and pre-colostrum porcine serum was examined. ... The viability of four strains of Bordetella bronchiseptica, two strains of B. ... The viability of four strains of Bordetella bronchiseptica, two strains of B. pertussis and one strain of B. parapertussis ...
If Bordetella pertussis Antibody, IgA by ELISA is 1.2 U/mL or greater, then Bordetella pertussis IgA Immunoblot testing will be ... then Bordetella pertussis IgG Immunoblot testing will be added; If Bordetella pertussis Antibody, IgM by ELISA is 1.2 U/mL or ... BORDETELLA PERTUSSIS ANTIBODIES, IGA, IGG AND IGM BY ELISA WITH REFLEX TO IMMUNOBLOT. Mnemonic ... 86615 x3 Bordetella (IgA, IgG, IgM), if reflexed, add 86615 for each Bordetella Immunoblot ...
Blue Cross Blue Shield of Massachusetts is a leading provider of quality health insurance for residents of Massachusetts. Our main goal is to make health care cost-effective by offering health insurance solutions for individuals, families, and large and small businesses at affordable rates.. Our Vision - Making Quality Health Care ...
Bordetella pertussis, the human pathogen of whooping cough, when grown at 22 degrees C is nonvirulent and unable to bind ... Adhesion of Bordetella pertussis to eukaryotic cells requires a time-dependent export and maturation of filamentous ... Adhesion of Bordetella pertussis to eukaryotic cells requires a time-dependent export and maturation of filamentous ... Adhesion of Bordetella pertussis to eukaryotic cells requires a time-dependent export and maturation of filamentous ...
Pertussis toxin, the major virulence factor of Bordetella pertussis, is not produced by the closely related species Bordetella ... Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes.. B Aricò, R ... Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes.. B Aricò, R ... Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes.. B Aricò, R ...
Bordetella pertussis. The micrograph shows the bacteriums surface covered in fine hairs called pili or frimbriae. Several ... Keywords: bacteria, bacterial, bacteriology, bacterium, betaproteobacteria, bordetella pertussis, electron micrograph, ... Caption: False colour transmission electron micrograph of the whooping cough bacterium, Bordetella pertussis. The micrograph ...
  • The toxin, known as pertussis toxin (or PTx), inhibits G protein coupling that regulates an adenylate cyclase-mediated conversion of ATP to cyclic AMP. (wikipedia.org)
  • These findings suggest that B. per- lia contains pertussis toxin (Ptx), pertactin (Prn), and fila- tussis not expressing Prn arose independently multiple mentous hemagglutinin (Fha). (cdc.gov)
  • How much (µg) pertussis toxin and filamentous hemaggluttinin are coated to the human ELISA IgG plates (per well)? (abcam.com)
  • Also, is the pertussis toxin the entire complex or just the S1 subunit? (abcam.com)
  • The pertussis toxin is the entire complex. (abcam.com)
  • Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. (asm.org)
  • Pertussis toxin, the major virulence factor of Bordetella pertussis, is not produced by the closely related species Bordetella parapertussis and Bordetella bronchiseptica. (asm.org)
  • Nucleotide sequencing of an EcoRI fragment of 5 kilobases comprising the regions homologous to the pertussis toxin genes shows that in this region, B. parapertussis and B. bronchiseptica are 98.5% and 96% homologous, respectively, to B. pertussis. (asm.org)
  • iii) the presence of pertussis toxin (PT)-, filamentous haemagglutinin (FHA)- or fimbriae (Fim)-deficient isolates. (eurosurveillance.org)
  • and shown to be a protective antigen in the mouse intracerebral protection assay when nonprotective levels of pertussis toxin were present ( 11 ). (asm.org)
  • Adenylate cyclase-hemolysin toxin (CyaA) produced from the human respiratory tract pathogen Bordetella pertussis requires fatty-acyl modification by CyaC-acyltransferase to become an active toxin. (sigmaaldrich.com)
  • Using data on 195 participants (≥7 years old) from an epidemiological study, we assessed the sensitivity, specificity, and performance (Youden index) for pertussis diagnosis of the pertussis toxin enzyme-linked immunosorbent assay (using single and paired serology) and of real-time PCR assays (using the IS 481 and ptxA -Pr targets). (asm.org)
  • Immunization with the Recombinant Cholera Toxin B Fused to Fimbria 2 Protein Protects against Bordetella pertussis Infection. (biomedsearch.com)
  • This study examined the immunogenic properties of the fusion protein fimbria 2 of Bordetella pertussis (Fim2)-cholera toxin B subunit (CTB) in the intranasal murine model of infection. (biomedsearch.com)
  • To this end B. pertussis Fim2 coding sequence was cloned downstream of the cholera toxin B subunit coding sequence. (biomedsearch.com)
  • Pertussis toxin CPTD enhanced aggregation of rabbit peritoneal and peripheral neutrophils and human peripheral neutrophils. (gla.ac.uk)
  • Studies on immunized children have suggested that high levels of circulating Abs against the B. pertussis virulence factors, pertussis toxin (PT), and pertactin may be important for protection ( 4 , 5 ). (jimmunol.org)
  • A characterisation has been made for the pertussis toxin (pt), the filamentery haemagglutinine (fha) and different lipopolysaccharides (lps). (rapidtest.com)
  • The use of purified materials confirmed that the presence of this pertussis toxin (PT) was responsible for the later peak in stimulation, whereas lipopolysaccharide (LPS) in combination with PT and also the filamentous haemagglutinin (FHA) could mimic the early peak of stimulation. (eurekamag.com)
  • The former document is a consensus document on laboratory guidance for the determination of serum Immunoglobulin G (IgG) anti-pertussis toxin antibodies to pertussis by enzyme-linked immunosorbent assay (ELISA) serology for European laboratories. (europa.eu)
  • Anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), and anti-pertactin (PRN) IgG titers were measured before primary vaccination, and before and after booster vaccination. (biomedcentral.com)
  • The quantitative determination of specific Immunoglobulin G antibodies to Bordetella pertussis toxin was done using a commercially available validated ELISA method. (biomedcentral.com)
  • Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange. (openrepository.com)
  • Journal Article] Polymorphisms Influencing Expression of Dermonecrotic Toxin in Bordetella bronchiseptica. (nii.ac.jp)
  • PCR was done using oligonucleotide primers PTp1 and PTp2 which amplify a 191-base pair DNA fragment of pertussis toxin operon. (ovid.com)
  • Recombinant, genetically-detoxified adenylate cyclase toxin (CyaA) constructs from Bordetella pertussis have been developed as potential antigen delivery systems and as promising antigen candidates for inclusion in acellular pertussis vaccines. (synbiosis.com)
  • This Pertussis toxin, CAS 70323-44-3, catalyzes ADP-ribosylation of guanine nucleotide-binding regulatory proteins Gi, Go, and Gt. (emdmillipore.com)
  • Ross, P.J., Lavelle, E.C., Mills, K.H.G. and A.P. Boyd `Adenylate cyclase toxin from Bordetella pertussis synergises with lipopolysaccharide to promote innate IL-10 production and enhance the induction of Th2 and regulatory T cells? (tcd.ie)
  • Adenylate cyclase toxin (CyaA) from Bordetella pertussis can subvert host immune responses allowing bacterial colonization. (tcd.ie)
  • The adenylate cyclase toxin, along with several other B. pertussis virulence factors, undergo a phase shift between states of expression and repression. (openrepository.com)
  • They may include pertussis toxin (PT), filamentous hemagglutin (FHA), Prn, or Fim2 and Fim3. (biomedcentral.com)
  • This rose to 92 % (105/114) if only samples positive for both of the two targets used for the B. pertussis PCR (insertion element IS 481 and pertussis toxin promoter ptxP ) were analysed. (microbiologyresearch.org)
  • Sequence-based typing of the pertactin, pertussis toxin S1 subunit and pertussis promoter regions ( prn , ptxA and ptxP ) was attempted on 89 of the DNA extracts that had generated a full MLVA profile. (microbiologyresearch.org)
  • Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. (microbiologyresearch.org)
  • First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. (microbiologyresearch.org)
  • Results for Bordetella culture and/or direct fluorescent antibody testing and a second LightCycler PCR assay (target, pertussis toxin gene) were compared to results of the LC-PCR-IS assay for 111 nasopharyngeal swabs submitted for pertussis testing. (elsevier.com)
  • Pertussis, also known as whooping cough , is a highly contagious respiratory disease. (cdc.gov)
  • After cough fits, someone with pertussis often needs to take deep breaths, which result in a "whooping" sound. (cdc.gov)
  • Bordetella pertussis is a Gram-negative, aerobic, pathogenic, encapsulated coccobacillus of the genus Bordetella, and the causative agent of pertussis or whooping cough. (wikipedia.org)
  • The paroxysmal cough precedes a crowing inspiratory sound characteristic of pertussis. (wikipedia.org)
  • Pertussis, also known as whooping cough, has recently re-emerged as a major public health threat despite high levels of vaccination against the aetiological agent Bordetella pertussis. (nih.gov)
  • Bordetella pertussis causes whooping cough, a severe respiratory tract infection in infants and children, and also infects adults. (nih.gov)
  • Bordetella pertussis was isolated from a patient with whooping cough. (thelabrat.com)
  • Originally named Haemophilus pertussis F Footnote 1 , Whooping cough Footnote 2 . (canada.ca)
  • B. pertussis is a respiratory pathogen that causes pertussis, also known as whooping cough, a localized infection of the ciliated epithelium of the bronchial tree Footnote 3 , Footnote 7 . (canada.ca)
  • The second stage is the paroxysmal stage, lasting for about 1-6 weeks, and is characterized by various pathognomonic symptoms of pertussis such as episodes of paroxysmal cough with a characteristic whooping sound. (canada.ca)
  • Atypical pertussis, a less severe respiratory illness which include prolonged, nonparoxysmal cough occurs mainly in older immunized children and adults Footnote 3 , Footnote 7 . (canada.ca)
  • Pertussis infection in infants may cause severe cough, choking, poor feeding, and apnea without paroxysmal cough Footnote 3 , Footnote 7 , Footnote 10 . (canada.ca)
  • False colour transmission electron micrograph (TEM) of a thin section of the whooping cough bacteria, Bordetella pertussis. (sciencephoto.com)
  • Bordetella pertussis, the human pathogen of whooping cough, when grown at 22 degrees C is nonvirulent and unable to bind eukaryotic cells. (pnas.org)
  • Bordetella pertussis, the main causative agent of whooping cough, is a reemerging pathogen, and recent vaccine-resistant strain outbreaks and emergence of macrolides-resistant strains in China raised new concerns for control of the disease. (medworm.com)
  • Infectious diseases such as smallpox, measles, diphtheria and pertussis (whooping cough) were once prevalent and killed indiscriminately. (medworm.com)
  • Pertussis or whooping cough is a highly contagious vaccine-preventable respiratory disease that resurged during the last decades in many countries. (medworm.com)
  • Despite high vaccination coverage, Bordetella pertussis the causative agent of whooping cough is still a health concern worldwide. (medworm.com)
  • For this study, we employed the same quantitative, immunofluorescent adherence assay to test the possibility that sera of patients recovering from naturally acquired whooping cough or immunized with pertussis vaccine may contain activity capable of interfering with this specific adherence. (asm.org)
  • Bordetella pertussis is the causative agent of the disease whooping cough. (asm.org)
  • Despite high pertussis vaccine coverage, reported cases of whooping cough (pertussis) have increased over the last decade in the United States and other developed countries. (pubmedcentralcanada.ca)
  • IMPORTANCE Whooping cough, primarily caused by Bordetella pertussis , has resurged in the United States even though the coverage with pertussis-containing vaccines remains high. (pubmedcentralcanada.ca)
  • Bordetella pertussis is the causative agent of whooping cough (pertussis), a respiratory disease with the highest morbidity and mortality in young infants. (pubmedcentralcanada.ca)
  • CyaA is crucial for colonization by Bordetella pertussis, the etiologic agent of whooping cough. (rcsb.org)
  • Immunization with whole cell pertussis vaccines (Pw) 3 is effective at preventing whooping cough in children. (jimmunol.org)
  • Whooping cough is a disease of the respiratory tracts which is caused by Bordetella pertussis bacteria. (rapidtest.com)
  • Pertussis or whooping cough is currently the most prevalent vaccine-preventable childhood disease despite >85% global vaccination coverage. (openrepository.com)
  • Bordetella pertussis is the etiological agent of whooping cough, a bacterial infection of especially children, which may be fatal without treatment. (biomedcentral.com)
  • In 2008 about 16 million cases of whooping cough-also designated as pertussis-resulting in almost 200,000 pediatric deaths were estimated by the World Health Organization, while for 2015 more than 60,000 deaths of infants were assumed [ 1 , 2 , 3 ]. (biomedcentral.com)
  • Bordetella pertussis , the gram-negative bacterium that causes whooping cough, still infects up to 40 million individuals each year and is responsible for around 300,000 annual deaths ( 27 ), despite a high worldwide vaccine coverage. (asm.org)
  • Since 2011, increases in the number of cases of pertussis, commonly known as whooping cough, have been repeatedly reported across the world, even in those with sustained high vaccination coverage. (europa.eu)
  • The guidance and protocol is intended for real-time PCR on DNA extracted from clinical specimens obtained from patients with suspected whooping cough (i.e. infection with Bordetella pertussis or B. parapertussis ). (europa.eu)
  • Both documents have been produced by the members of the European Bordetella expert group 'EUpert-Labnet' as part of "Coordination of activities for laboratory surveillance of whooping cough in Member States and EEA countries" project. (europa.eu)
  • We tried to identify a causative factor of Bordetella pertussis that causes paroxysmal coughing in the human infection, whooping cough. (nii.ac.jp)
  • For this purpose, we established an animal experimental model that replicates coughing similar to that observed in whooping cough by using B. bronchiseptica, which is closely related to B. pertussis. (nii.ac.jp)
  • Bordetella pertussis is the causative agent of whooping cough, a respiratory disease still considered as a major public health threat and for which recent re-emergence has been observed. (altmetric.com)
  • We have previously identified three novel loci that influence the severity of whooping cough by using recombinant congenic strains of mice: Bordetella pertussis susceptibility loci 1, 2, and 3 (Bps1, -2, and -3). (synbiosis.com)
  • The genetic composition of the bacterium causing whooping cough, Bordetella pertussis , has been investigated using microarray studies in order to examine potential genetic contributors to the disease re-emergence in the past decade. (biomedcentral.com)
  • B. pertussis are the bacteria that cause pertussis, or whooping cough. (baylorhealth.com)
  • Clinicians should consider pertussis in the differential diagnosis of persistent cough illness in people of all ages - even those previously immunised. (cancerscreening.gov.au)
  • Whooping cough, caused by the bacterium Bordetella pertussis , is a highly contagious respiratory disease that can cause serious illness or death among infants and young children. (cancerscreening.gov.au)
  • In April 1999, within a remote community in the Gascoyne region of WA, an elderly male with a history of chronic cough was diagnosed as having B. pertussis by IgA serology. (cancerscreening.gov.au)
  • On 24 November, after a woman and her daughter presented with a persistent cough, a local general practitioner concerned about pertussis contacted the Gascoyne Public Health Unit (PHU) and organised nasopharyngeal aspirates. (cancerscreening.gov.au)
  • Bordetella pertussis is the causative agent of human whooping cough (pertussis) and is particularly severe in infants. (biomedcentral.com)
  • Bordetella pertussis is the causative agent of whooping cough, a highly contagious disease of the respiratory tract in humans. (biomedcentral.com)
  • Mycoplasma pneumoniae and Chlamydophila pneumoniae (atypical pathogens) and Bordetella pertussis ('pertussis' or 'whooping cough') respiratory tract infections are often diagnosed clinically while waiting for laboratory results to come back, which take days. (isrctn.com)
  • Whooping cough (pertussis) is a consequence of upper respiratory tract colonisation by B. pertussis and is characterised by symptoms such as fever and coughing, which persist for more than a week. (fiocruz.br)
  • Pertussis is a highly infectious vaccine-preventable cough illness that continues to be a significant source of morbidity and mortality around the world. (asmscience.org)
  • Pertussis (whooping cough) is a severe respiratory disease in children caused by a bacterial infection with Bordetella pertussis - the mortality rate is 0.5% in infants under six months. (roche.com)
  • The disease pertussis, more commonly known as whooping cough, is caused by the gram negative bacterium Bordetella pertussis. (openrepository.com)
  • Bordetella pertussis is a causative agent of pertussis or whooping cough in humans. (biomedcentral.com)
  • Pertussis or whooping cough is an infectious respiratory disease caused by the bacterium Bordetella pertussis . (biomedcentral.com)
  • 30% (96/320) of B. pertussis isolates did not express the (ACV) was developed in the 1980s. (cdc.gov)
  • Although ACV formulations differ in the number of sion of Prn in 16 (17%) isolates could not be determined component pertussis antigens, the vaccine used in Austra- at the sequence level. (cdc.gov)
  • Rapid Increase in Pertactin-deficient B. pertussis of age) and increased use of more sensitive diagnostic tests, A total of 126 additional isolates collected from Westmead such PCR ( 4 ). (cdc.gov)
  • In a dot enzyme immunoassay, HBp2 reacted with all B. pertussis strains and clinical isolates tested except for four atypical variant strains of the LOS B phenotype. (nih.gov)
  • High prevalence of pertactin (PRN)-deficient Bordetella pertussis isolates has been found in these countries. (eurosurveillance.org)
  • B. pertussis clinical isolates were obtained from different European countries during four periods (EUpert I-IV studies): 1998 to 2001 (n = 102), 2004 to 2005 (n = 154), 2007 to 2009 (n = 140) and 2012 to 2015 (n = 265). (eurosurveillance.org)
  • Although Bordetella pertussis is well known for its limited gene sequence variation, recent advances in long-read sequencing technology have begun to reveal genomic structural heterogeneity among otherwise indistinguishable isolates, even within geographically or temporally defined epidemics. (pubmedcentralcanada.ca)
  • We have compared rearrangements among complete genome assemblies from 257 B. pertussis isolates to examine the potential evolution of the chromosomal structure in a pathogen with minimal gene nucleotide sequence diversity. (pubmedcentralcanada.ca)
  • It is also required for the determination of the appropriate vaccine strain and the antimicrobial susceptibility of isolates in order to control the spread of pertussis ( 12 , 13 ). (pubmedcentralcanada.ca)
  • Bordetella pertussis isolates in Finland: serotype and fimbrial expression. (openrepository.com)
  • Bordetella pertussis isolates lacking pertactin, a key antigen component of the acellular pertussis vaccine, have been observed, suggesting that B. pertussis is losing pertactin in response to vaccine immunity. (asm.org)
  • Screening of 1,300 isolates from outbreak and surveillance studies (historical isolates collected from 1935 up to 2009, isolates from the 2010 California pertussis outbreak, U.S. isolates from routine surveillance between 2010-2012, and isolates from the 2012 Washington pertussis outbreak) by conventional PCR and later by Western blotting and prn sequencing analyses ultimately identified 306 pertactin-deficient isolates. (asm.org)
  • All Bordetella pertussis isolates were macrolide-resistant, harbored prn1/ptxP1/fim3-1 as previously reported and belonged to multilocus variable tandem repeat analysis type MLVA 195. (ovid.com)
  • Regions of difference (RDs) have been previously identified as clusters of genes flanked by insertion sequences which are variably present in different sets of isolates, and have also been shown to be potential markers of B. pertussis evolution. (biomedcentral.com)
  • A B. pertussis specific mPCR/RLB using 43 genes representing 30 RDs, was developed and used to characterise a set of 42 B. pertussis isolates. (biomedcentral.com)
  • We previously used single nucleotide polymorphisms (SNPs) to characterise an international collection of over 300 B. pertussis isolates. (biomedcentral.com)
  • These isolates were differentiated into 42 unique SNP profiles (SPs) and six distinct clusters (clusters I to VI) [ 14 ], with recently emerging isolates in cluster I. In this study, we used representative isolates of each of the 42 SPs to develop an inexpensive specific mPCR/RLB to further determine the genome variation in B. pertussis . (biomedcentral.com)
  • In an attempt to gain insight into the genomic make-up of B. pertussis over the last 60 years, we used an oligonucleotide DNA microarray to compare the genomic contents of a collection of 171 strains of B. pertussis isolates from different countries. (biomedcentral.com)
  • An overview of genomic contents of a large collection of isolates from different countries allowed us to derive a core genome and a phylogenetic structure of B. pertussis . (biomedcentral.com)
  • We examined the regulation of fimbrial expression in B. pertussis clinical isolates. (pasteur.fr)
  • Molecular typing of Bordetella pertussis is routinely performed on bacterial isolates, but not on DNA extracted from nasopharyngeal aspirates or pernasal swabs submitted for diagnostic real-time PCR (qPCR). (microbiologyresearch.org)
  • Comparison of molecular typing data from the 89 extracts with those from 111 contemporary bacterial isolates showed that the two sources yielded the same picture of the B. pertussis population [dominated by the MLVA-27 prn (2) ptxA (1) ptxP (3) clonal type]. (microbiologyresearch.org)
  • Subtractive hybridization was carried out to identify differences between the sequenced genome of Bordetella pertussis Tohama I and those of two recently collected isolates. (pasteur.fr)
  • 2020 Sep 28;137:155313 Authors: da Silva Antunes R, Quiambao LG, Soldevila F, Sutherland A, Peters B, Sette A Abstract Bordetella Pertussis (BP) vaccine-induced immunity is waning worldwide despite excellent vaccine coverage. (medworm.com)
  • Whole-cell pertussis vaccines have been shown to selectively induce T helper 1 (Th1)-type responses in human and animals. (nih.gov)
  • Acellular vaccines against Bordetella pertussis were implementation of immunization with a whole-cell vaccine introduced in Australia in 1997. (cdc.gov)
  • Whole cell pertussis vaccines (wP) are effective, but reactogenic, and have been replaced in most developed countries by acellular pertussis vaccines (aP). (nih.gov)
  • Pertussis outbreaks have occurred in several industrialised countries using acellular pertussis vaccines (ACVs) since the 1990s. (eurosurveillance.org)
  • A resurgence of pertussis cases has been reported, particularly in countries using acellular vaccines with waning immunity and pathogen adaptation thought to be responsible. (medworm.com)
  • The mouse body weight gain test (MWGT), the leukocytosis-promoting test (LPT), and the histamine sensitization test (HIST) are done for the testing of the specific toxicity of pertussis vaccines. (omicsonline.org)
  • The introduction of vaccines against pertussis during the 1940s dramatically reduced the disease incidence in the United States. (pubmedcentralcanada.ca)
  • However, despite high or increasing coverage with pertussis-containing vaccines, the number of reported pertussis cases in the United States and many other developed countries has increased over the last decade, with notable recent epidemics ( 1 , - 3 ). (pubmedcentralcanada.ca)
  • Whole cell pertussis vaccines (Pw) induce Th1 responses and protect against Bordetella pertussis infection, whereas pertussis acellular vaccines (Pa) induce Ab and Th2-biased responses and also protect against severe disease. (jimmunol.org)
  • However, Pw have been associated with a number of local and systemic reactions, and although still used in developing countries, have been replaced in developed countries by acellular pertussis vaccines (Pa), prepared with highly purified Ags from Bordetella pertussis administered with alum as the adjuvant ( 1 , 2 ). (jimmunol.org)
  • Unlike other pertussis vaccines, BPZE1 has been shown to provide strong protection against infection by the causative agent of pertussis, Bordetella pertussis, in non-human primates. (openrepository.com)
  • Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. (openrepository.com)
  • Bordetella pertussis fimbriae (Fim): relevance for vaccines. (openrepository.com)
  • In frame of studies to investigate putative effects of vaccination on host-pathogen interaction and clonal distribution of strains, in addition to Corynebacterium diphtheriae and Clostridium tetani toxoid vaccines, also whole-cell and acellular pertussis vaccines were analyzed by mass spectrometry. (biomedcentral.com)
  • LC-MS/MS spectra were generated and analyzed using B. pertussis genome data and proteins present in whole-cell and acellular pertussis vaccines were identified. (biomedcentral.com)
  • Whole-cell vaccines are suspensions of killed B. pertussis cells, while the acellular pertussis vaccines, which were developed to prevent unwanted local reactions of the whole-cell vaccine, contain only a limited number of purified components (for overview of different vaccine formulations see [ 3 ]. (biomedcentral.com)
  • The data represent proteomic analyses of commercially vaccines, an acellular and a whole cellular pertussis vaccine. (biomedcentral.com)
  • Bordetella pertussis vaccines are typically administered in combination with diphtheria and tetanus toxoid vaccines as DTP3 vaccines. (biomedcentral.com)
  • However, the immune mechanism of protection against B. pertussis and, consequently, the optimal way to administer pertussis vaccines, especially in young children, are still insufficiently understood. (asm.org)
  • After booster vaccination, no significant difference was observed between the two vaccines in antibody titers against pertussis antigens ( P = 0.53 for anti-PT IgG, P = 0.91 for anti-FHA IgG, P = 0.39 for anti-PRN IgG). (biomedcentral.com)
  • When mapped against the previously identified evolutionary relationships of the strains, the losses of two RDs - BP0910A - BP00930 and BP1948-BP1962 - were found to be associated with significant events in B. pertussis history: the loss of BP0910A - BP00930 coincided with introduction of whole cell vaccines in the 1950s while that of BP1948-BP1962 occurred after the introduction of acellular vaccines. (biomedcentral.com)
  • 2 The school entry dose was introduced in August 1994 and acellular pertussis vaccines replaced whole cell ones for booster doses in Western Australia (WA) in February 1997 (Source: Perth Immunisation Clinic). (cancerscreening.gov.au)
  • Although immunisation with a cellular vaccine was effective in the late XX century, this type of vaccine has been replaced by acellular pertussis vaccines in several countries due to its side effects. (fiocruz.br)
  • Pertactin (Prn), fimbriae 2 (Fim2) and fimbriae 3 (Fim3) of B. pertussis are important virulence factors and immunogens which have been included in some acellular pertussis vaccines. (biomedcentral.com)
  • Our results indicated that the recombinant proteins still retain their immunological properties and highlighted the potential of the recombinant proteins for the future development of the B. pertussis vaccines. (biomedcentral.com)
  • Southern blot analysis indicates that strains of Bordetella bronchiseptica and Bordetella parapertussis have DNA homologous to vag-8 . (asm.org)
  • Strains of Bordetella were grown on Bordet-Gengou (BG) medium supplemented with 12% sheep blood or in cyclodextrin solid medium (CSM) ( 1 ). (asm.org)
  • The work was done with crude fractions and purified components of the bacterium and also whole-cells of mutant strains and of antigenically-modulated variants of B. pertussis. (gla.ac.uk)
  • The concentration of cefdinir was set by the MIC data from 50 clinical strains of M. catarrhalis and 40 clinical strains of B. pertussis . (pubmedcentralcanada.ca)
  • Also a change in the fimbrial serotype of B. pertussis strains was observed from serotype Fim2 predominantly found in unvaccinated populations to serotype Fim3 and serotype Fim2,3 in vaccinated populations [ 9 ]. (biomedcentral.com)
  • We therefore screened 11 inbred strains of mice for susceptibility to a pertussis infection after intranasal infection. (synbiosis.com)
  • By comparing the presence or absence of RDs, we aimed to determine the genomic variability of a diverse collection of B. pertussis strains and how they have changed over time. (biomedcentral.com)
  • The loss of BP1948-BP1962 also coincided with expansion of the most recent B. pertussis strains. (biomedcentral.com)
  • The mPCR/RLB assay offers an inexpensive and fast method of determining the gene content of B. pertussis strains and also confirms that gene losses are an ongoing feature of B. pertussis evolution. (biomedcentral.com)
  • Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? (biomedcentral.com)
  • The CGH microarray analysis estimated the core genome of B. pertussis , to consist of 3,281 CDSs that are conserved among all B. pertussis strains, and represent 84.8% of all CDSs found in the 171 B. pertussis strains. (biomedcentral.com)
  • CGH data also revealed that the genome size of B. pertussis strains is decreasing progressively over the past 60 years. (biomedcentral.com)
  • B. pertussis strains with the same gene content were found in several different countries. (biomedcentral.com)
  • However, geographic specificity of the B. pertussis strains was not observed. (biomedcentral.com)
  • The emergence of strains harbouring allelic variants of the antigens used in vaccine development is one of the possible causes of pertussis resurgence. (fiocruz.br)
  • 2010). A recent study based on whole-genome analyses evaluated B. pertussis strains recovered worldwide, though no Brazilian strain was included. (fiocruz.br)
  • 2014). Although there has been a lack of characterisation of strains circulating in Brazil, pertussis has also reemerged in this country. (fiocruz.br)
  • B. pertussis, B. parapertussis and B. bronchiseptica form a closely related phylogenetical group. (wikipedia.org)
  • Antiserum raised to a fusion of maltose binding protein to an N-terminal 60-kDa fragment of Vag8 recognizes the native 95-kDa protein in immunoblots of B. pertussis and B. bronchiseptica but not B. parapertussis . (asm.org)
  • The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model. (rivm.nl)
  • Bordetella pertussis or B. parapertussis). (europa.eu)
  • 28 grew B. pertussis and 9 grew B. parapertussis. (ovid.com)
  • The genus Bordetella consists of Gram-negative β -proteobacteria, including the three human pathogens Bordetella pertussis , Bordetella parapertussis and Bordetella bronchiseptica , which are considered the classical Bordetella species (van der Zee et al. (fiocruz.br)
  • Common targets for detection of B. pertussis and B. parapertussis are the insertion sequences (IS). (roche.com)
  • A rapid real-time multiplex PCR assay for detecting and differentiating Bordetella pertussis and Bordetella parapertussis in nasopharyngeal swabs was developed. (elsevier.com)
  • This assay (LC-PCR-IS) targets the insertion sequences IS481 and IS1001 of B. pertussis and B. parapertussis, respectively, and is performed using the LightCycler (Roche Molecular Biochemicals, Indianapolis, Ind. (elsevier.com)
  • Of the specimens, 12 were positive (9 B. pertussis and 3 B. parapertussis) and 68 specimens were negative by all methods. (elsevier.com)
  • All of these characteristics represent a significant improvement in the detection of B. pertussis and B. parapertussis in nasopharyngeal specimens. (elsevier.com)
  • The heterohybridoma cell line HBp2 secreting human monoclonal antibody (hMAb) directed against Bordetella pertussis was generated by fusing SP2/HPT heteromyeloma cells with human spleen lymphocytes, after in vitro stimulation for 6 days. (nih.gov)
  • Together these studies suggested that HBp2 is reactive with carbohydrate epitopes present on the LOS A. Binding assays with live bacteria demonstrated that hMAb HBp2 reacted with cell surface exposed epitopes on B. pertussis but the antibody did not bind significantly to the surface on intact B. bronchiseptica cells. (nih.gov)
  • Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells. (asm.org)
  • Suppression of the antibody response occurred when pertussis cells were injected at the same time as an optimal immunizing dose of SIII. (jimmunol.org)
  • In contrast, the antibody response to high doses of SIII was enhanced by B. pertussis. (jimmunol.org)
  • However, when B. pertussis was administered with either optimal or high doses of SIII, 7S as well as 19S antibody against SIII was produced. (jimmunol.org)
  • Only one adult human serum, from a physician constantly working with B. pertussis, inhibited the mitogenic response to LPF and this serum was shown to contain precipitating antibody against LPF. (eurekamag.com)
  • The Diagnostic Automation Bordetella pertussis IgA Antibody ELISA Test Kit has been designed for the detection and the quantitative determination of specific IgA antibodies against Bordetella pertussis in serum and plasma. (rapidtest.com)
  • The Diagnostic Automation Bordetella pertussis IgA antibody test kit is based on the principle of the enzyme immunoassay (EIA). (rapidtest.com)
  • Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. (openrepository.com)
  • Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease. (openrepository.com)
  • The humoral side of the adaptive immunity was initially considered the main effector of protection against B. pertussis , but there appears to be no direct correlation between serum antibody titers and protection ( 6 , 7 ). (asm.org)
  • Using a murine respiratory challenge model we have previously demonstrated a role for Th1 cells in natural immunity against Bordetella pertussis , but could not rule out a role for antibody. (rupress.org)
  • You need info about Human Bordetella pertussis IgM antibody ELISA Kit or any other Gentaur produtct? (gentaurshop.com)
  • The complete B. pertussis genome of 4,086,186 base pairs was published in 2003. (wikipedia.org)
  • Bordetella pertussis strain Tohama I, complete genome. (atcc.org)
  • BX470248 Bordetella pertussis strain Tohama I, complete genome. (atcc.org)
  • These data illustrate that structural genome evolution in B. pertussis is not limited to reduction but also includes rearrangement. (pubmedcentralcanada.ca)
  • The chromosome of B. pertussis includes a large number of repetitive mobile genetic elements that obstruct genome analysis. (pubmedcentralcanada.ca)
  • Constant reshuffling of Bordetella pertussis genome organization was observed during evolution. (altmetric.com)
  • A repetitive insertion sequence, IS481, has been found to be present in up to 100 copies within the genome of B. pertussis. (loinc.org)
  • Here, the genome of a clinical Bordetella pertussis strain (Bz181) that was recently isolated in Brazil is reported. (fiocruz.br)
  • Here, we report the first B. pertussis genome sequence of a clinical strain isolated in the northeastern region of Brazil (Bz181), in 2013. (fiocruz.br)
  • Bordetella pertussis is the gram-negative coccobacil- doses of ACV at 2, 4, and 6 months of age, and a booster lus that causes the respiratory disease pertussis, also vaccination at 4 years of age. (cdc.gov)
  • Laboratory confirmation of pertussis is integral to surveillance, especially to monitor the effectiveness of vaccination strategies and inform any changes to national policies. (europa.eu)
  • The findings suggest that natural infection or vaccination are associated with the acquisition of serum activity inhibiting the adherence of B. pertussis to ciliated cells. (asm.org)
  • However, vaccination with BPZE1f3 provided significantly stronger protection against Fim3-only producing B. pertussis than vaccination with BPZE1, indicating that immune responses to fimbriae contribute to serotype-specific protection against B. pertussis infection. (openrepository.com)
  • These numbers of worldwide cases illustrate that pertussis is a continuing threat to children's health and vaccination is important to prevent this infection. (biomedcentral.com)
  • Tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccination during adolescence was introduced in response to the resurgence of pertussis in various countries. (biomedcentral.com)
  • In Sri Lanka pertussis continues to circulate in the community and cases among adolescents and adults have been reported despite 95% coverage of the four dose pertussis vaccination during early childhood. (biomedcentral.com)
  • Therefore information on immunity to pertussis in the adolescent group is needed prior to considering vaccination schedule changes. (biomedcentral.com)
  • 90%) in the incidence and mortality due to pertussis was observed following large-scale vaccination during the 1950s and 1960s [ 7 ]. (biomedcentral.com)
  • Prevention of pertussis outbreaks depends not only on high vaccination coverage among young children but also early diagnosis and management of cases and their contacts. (cancerscreening.gov.au)
  • In most industrialized countries, generalized vaccination with a whole cell pertussis vaccine (WCV) began between 1950 and 1960. (biomedcentral.com)
  • Immunization schedules and the type of vaccine used began to differ in each country, leading to disparities in pertussis vaccination histories. (biomedcentral.com)
  • In the Netherlands, pertussis vaccination, using a WCV produced by the Netherlands Vaccine Institute, was introduced in 1953. (biomedcentral.com)
  • This study indicated the existence of at least two major B. pertussis lineages related to the pre and post-vaccination periods (Harvill et al. (fiocruz.br)
  • It is caused by the bacterium Bordetella pertussis . (cdc.gov)
  • Bordetella pertussis, a human pathogenic bacterium, produces either one or two types of serologically distinct fimbriae, Fim2 and Fim3, as virulence factors. (pasteur.fr)
  • La tos ferina es una enfermedad del tracto respiratorio que se presenta exclusivamente en los seres humanos y es causada por la bacteria gramnegativa Bordetella pertusis. (prezi.com)
  • Here, we developed a scalable, rapid, high-throughput luminescence-based Bordetella growth inhibition assay (BGIA) to quantify surviving bacteria after treatment with anti-B. pertussis compounds. (medworm.com)
  • When fixed, paraffin-embedded sections of human cancers were re-hydrated, incubated with B. pertussis , and then stained with LPHA for β1,6-branched N-glycans, bacteria were seen attached specifically to the sugar-rich regions of the tumors. (aacrjournals.org)
  • Regarding safety, i.v.-injected B. pertussis showed no toxicity toward the mice after repeated injections of the highest dose of bacteria tested (5 × 10 8 cfu/mouse). (aacrjournals.org)
  • The induction of protective Th1 responses by previous infection with B. pertussis or by immunization with Pw has been associated with IL-12 production by macrophages or dendritic cells (DC), and this has been linked with LPS and active PT present in the live bacteria and residual endotoxin in Pw preparations ( 14 ). (jimmunol.org)
  • The cellular immune responses of Balb/c mice and Wistar rats immunized in hind footpads with intact killed Bordetella pertussis were found to differ from those of similar animals immunized with other bacteria including Bordetella bronchiseptica, Salmonella typhimurium and Escherichia coli. (eurekamag.com)
  • Whole cell pertussis vaccine (wP) which is composed of killed entire bacteria induces a broad immune response against many bacterial antigens (including PT, FHA). (biomedcentral.com)
  • The B. pertussis Bz181 strain is deposited in the Collection of Bacteria of the Environment and Health at the Oswaldo Cruz Foundation (Fiocruz), Brazil. (fiocruz.br)
  • Recipients of CD4+ T cells cleared the bacteria from the lungs within 20 days of challenge, at which time B. pertussis-specific antibodies in the serum were undetectable. (tcd.ie)
  • Typically current APVs are comprised of antigens directly purified from cultured B. pertussis bacteria. (biomedcentral.com)
  • Like B. bronchiseptica, B. pertussis is motile and expresses a flagellum-like structure. (wikipedia.org)
  • When examined for bactericidal activity in the presence of complement, hMAb HBp2 showed high lytic capability against B. pertussis while no killing was obtained against B. bronchiseptica. (nih.gov)
  • Journal Article] The bvg-repressed gene brtA, encoding biofilm-associated surface adhesin, is expressed during host infection by Bordetella bronchiseptica. (nii.ac.jp)
  • Journal Article] Detection of genes expressed in Bordetella bronchiseptica colonizing rat trachea by in vivo expressed-tag immunoprecipitation method. (nii.ac.jp)
  • This antigen merits further investigation as a potentially important component in human immunity to B. pertussis infection. (nih.gov)
  • Our findings also demonstrate that activation of innate immune cells through TLR4 helps to direct the induction of Th1 and Th-17 cells, which mediate protective cellular immunity to B. pertussis . (jimmunol.org)
  • However, despite a reduction in IFN-γ production, the rate of bacterial clearance is not significantly lower following B. pertussis challenge of naive or Pw-immunized IL-12p35-defective mice (M. T. Brady and K. H. G. Mills, unpublished observation), suggesting a redundant role for IL-12 in protective adaptive immunity to B. pertussis . (jimmunol.org)
  • Although the exact causative factors are yet to be defined for the persistent circulation of pertussis, it may be due to the following reasons: waning of immunity induced by immunization, better awareness of the disease, improvement of the diagnostic methods and adaptation of Bordetella pertussis to survive in vaccinated populations. (biomedcentral.com)
  • Even in highly immunised populations periodic pertussis outbreaks are inevitable reflecting a vaccine efficacy of about 80 per cent and waning immunity with increasing age. (cancerscreening.gov.au)
  • Reasons for the resurgence of reported pertussis may include molecular changes in the organism and increased awareness and diagnostic capabilities, as well as lessened vaccine efficacy and waning immunity. (asmscience.org)
  • Mills, K.H.G., Barnard, A.L., Watkins, J. and Redhead, K. `Cell mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model? (tcd.ie)
  • A murine respiratory infection model was used to study the mechanism of protective immunity to Bordetella pertussis. (tcd.ie)
  • Although we do not rule out a contribution of mucosal immunoglobulin A, our findings suggest that cellular responses mediated by CD4+ Th1 cells play an important role in protective immunity to B. pertussis. (tcd.ie)
  • The hMAb HBp2, an IgM, reacted with untreated and proteinase K-treated B. pertussis outer membrane antigens, whereas the reactivity was lost when the antigen was treated with sodium periodate. (nih.gov)
  • A 96-well plate has been precoated with Bordetella pertussis antigens to bind cognate antibodies. (abcam.com)
  • B. pertussis invasion of SKmel-23 cells was inhibited by preincubation of cancer cells with glycosidase F, the plant lectins LPHA and TGP, human antibodies vs CD15 and CD11b, or the RGD tripeptide sequence-implying that the structural requirements for invasion included β1,6-branched N-glycans, Lewis × antigens, CD11b, and the sequence arg-gly-asp respectivelly. (aacrjournals.org)
  • Circulating mononuclear cells from B. pertussis -infected and from pertussis-vaccinated infants secrete high amounts of IFN-γ after in vitro stimulation by B. pertussis antigens, but with a large variation in the secreted IFN-γ levels between individuals. (asm.org)
  • T lymphocytes from both naturally infected children and from vaccinated subjects secrete IFN-γ in response to in vitro stimulation with B. pertussis antigens ( 15 , 16 , 22 ). (asm.org)
  • Therefore, we investigated here whether IL-10 secretion in infants vaccinated with an acellular vaccine against B. pertussis plays a role in the high interindividual variations of the specific IFN-γ responses to B. pertussis antigens. (asm.org)
  • Helical structure of Bordetella pertussis fimbriae. (asm.org)
  • The helical structures of Bordetella pertussis fimbriae of serotypes 2 and 6 were determined by optical diffraction analysis of electron micrographs of negatively stained paracrystalline bundles of purified fimbriae. (asm.org)
  • BPZE1 is a derivative of the B. pertussis strain Tohama I, which produces serotype 2 (Fim2) but not serotype 3 fimbriae (Fim3). (openrepository.com)
  • Fimbriae (Fim), also known as pili and agglutinogen, belong to bacterial adhesins which are expressed on the B. pertussis surface. (biomedcentral.com)
  • Infants below the age of 12 months have the highest incidence and mortality associated with pertussis. (canada.ca)
  • This study included 404 household contacts of 94 young infants (≤6 months of age) with laboratory-confirmed pertussis. (asm.org)
  • DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five dose series in infants and children 6 weeks through 6 years of age (prior to 7 th birthday). (nih.gov)
  • This specific IFN-γ secretion is at least partially induced by interleukin-12 (IL-12), as suggested by the strong correlation between B. pertussis -specific IFN-γ and IL-12 secretion levels, both in infected and in vaccinated infants ( 15 , 16 ). (asm.org)
  • However, although most vaccinated infants develop specific Th1 responses, these responses are very heterogeneous, according to the type of pertussis vaccine, and they are sometimes lower than detectable levels in peripheral blood. (asm.org)
  • The susceptibility to and the severity of Bordetella pertussis infections in infants and children varies widely, suggesting that genetic differences between individuals influence the course of infection. (synbiosis.com)
  • Pertussis shows a significant mortality rate in infants and was one of the most frequent and severe disease in this group before the worldwide introduction of an immunisation programme in the 1950s. (fiocruz.br)
  • The most morbidity and mortality with pertussis infection is seen in infants too young to benefit from immunization. (asmscience.org)
  • 2013. Characteristics of severe Bordetella pertussis infection among infants ≤90 days of age admitted to pediatric intensive care units-Southern California, September 2009-June 2011. (asmscience.org)
  • Severe pulmonary hypertension associated with shock and death in infants infected with Bordetella pertussis. (qxmd.com)
  • Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. (qxmd.com)
  • Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? (qxmd.com)
  • The purified lymphocytosis promoting factor (LPF) from Bordetella pertussis was found to be a potent mitogen for peripheral blood lymphocytes (PBL) from normal adults as well as for cord blood lymphocytes. (eurekamag.com)
  • The in vitro effects of Bordetella pertussis lymphocytosis-promoting factor on murine lymphocytes. (rupress.org)
  • The mitogenic response of murine lymphocytes to the lymphocytosis-promoting factor of Bordetella pertussis has been shown to be due to activation of T cells. (rupress.org)
  • B. pertussis is of worldwide prevalence as it can exist as a noninvasive parasite of the respiratory tract of mammals, however, 20-40 million cases of pertussis, and 400,000 fatal cases, are reported each year Footnote 9 . (canada.ca)
  • In the United States, the rates of pertussis infection moderately increased between the years 1980 and 2000, although larger rate increases were observed in adolescent and adult cases of pertussis Footnote 2 , Footnote 9 . (canada.ca)
  • However pertussis continues to circulate in the communities and estimates from WHO suggest that in 2008 about 16 million cases of pertussis occurred worldwide, 95% of which were reported in developing countries [ 7 ]. (biomedcentral.com)
  • All 21 cases of pertussis among the group under 10 years of age were at least partially vaccinated. (cancerscreening.gov.au)
  • Sections were obtained from the lungs of mice receiving saline, an OVA-challenge, and an OVA-challenge and heat-killed B. pertussis (2 × 10 10 cells) 1 day before the first airway challenge. (nih.gov)
  • B. pertussis targeted A549 human lung carcinomas growing s.c. in nu / nu mice. (aacrjournals.org)
  • A 95-kDa protein-negative derivative of B. pertussis 18323 containing a deletion of vag-8 colonized mice as efficiently as the parent B. pertussis strain in a mouse aerosol model of pertussis. (asm.org)
  • Aerosol infection of mice with Bordetella pertussis. (asm.org)
  • Aerosol inhalation of Bordetella pertussis Tohama phase I resulted in a reproducible and uniform infection of mice (strain DDY or ICR). (asm.org)
  • Subsequent studies using a 30-min aerosol inoculation of ICR mice with 2 X 10(9) bacterial cells per ml showed: (i) B. pertussis cells reached a maximum of about 10(7) colony-forming units per lung 14 days after inhalation. (asm.org)
  • In addition, we identified a new effector function for IL-17, activating macrophage killing of B. pertussis , and this bactericidal activity was less efficient in macrophages from TLR4-defective mice. (jimmunol.org)
  • The effect of an i.p. injection of Bordetella pertussis on the primary humoral immune response in mice to the thymus-independent antigen SIII has been studied. (jimmunol.org)
  • In mice, recovery from infection is associated with the development of B. pertussis -specific Th1 cells, and the adoptive transfer of these Th1 cells from convalescent mice confers protection to the recipient mice ( 18 ). (asm.org)
  • Splenocytes from infected C3H/HeJ mice produced almost no interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α) upon ex vivo restimulation with B. pertussis compared to A/J mice and also showed a delayed gamma interferon (IFN-γ) production. (synbiosis.com)
  • Here we have demonstrated that B. pertussis respiratory infection of mice with targeted disruptions of the genes for the IFN-γ receptor resulted in an atypical disseminated disease which was lethal in a proportion of animals, and was characterized by pyogranulomatous inflammation and postnecrotic scarring in the livers, mesenteric lymph nodes and kidneys. (rupress.org)
  • Bacterial culture for diagnosing pertussis infection has high specificity but poor sensitivity and is slow. (asm.org)
  • This study described a pertussis outbreak caused by macrolide-resistant B. pertussis in a primary school and indicated that close contact of index case causes the bacterial transmission. (ovid.com)
  • Between the years 1998-2004, the incidence of pertussis as well as pertussis-related mortality declined significantly following introduction of the acellular pertussis vaccine (DTaP-IPV-Hib vaccine) in 1998 Footnote 7 . (canada.ca)
  • Extensive immunization of children reduced the incidence of serious disease and mortality caused by B. pertussis [ 7 ]. (biomedcentral.com)
  • From 1975 to 1985 a lower vaccine dose was used, which most likely lead to an increase in the incidence of pertussis between 1985 to 1987 [ 21 ]. (biomedcentral.com)
  • After restoring the vaccine to the normal dose, a lower incidence of pertussis was noted until 1996. (biomedcentral.com)
  • However, since 1996, the pertussis incidence has increased. (biomedcentral.com)
  • Since the introduction of the acellular pertussis vaccine, the number of reported pertussis cases has drastically decreased. (pubmedcentralcanada.ca)
  • In this Review, we describe the pathogenesis of this disease, with a focus on recent mechanistic insights into B. pertussis virulence-factor function. (nih.gov)
  • Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. (openrepository.com)
  • Abcam's anti-Bordetella pertussis IgG Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgG class antibodies against Bordetella pertussis in Human serum and plasma. (abcam.com)
  • The National Immunization Commission and the National Program for the Control of Vaccine-Preventable Diseases (Programa Nacional de Control de Enfermedades Inmunoprevenibles, ProNaCEI) updated the immunization policy in relation to Bordetella pertussis (BP) in 2009 in order to improve the control of this disease in accordance with international recommendations. (scielo.org.ar)
  • Thus pertussis remains a poorly controlled vaccine preventable diseases in the world. (biomedcentral.com)
  • In the 1990s, pertussis reemerged even in countries with highly vaccinated populations and it is currently the most prevalent vaccine-preventable disease, representing a public health threat even in developed countries (Hartzell & Blaylock 2014). (fiocruz.br)
  • The B. pertussis ASR contains primers and a FAM-labeled probe that is designed to detect a 103 bp region of the IS481 gene. (bio-medicine.org)
  • The S1 subunits of both species, when expressed in Escherichia coli, have the same ADP-ribosylating activity as the S1 subunit from B. pertussis, indicating that the mutations in the S1 gene described here do not affect its function. (asm.org)
  • All the 12 DNAs had the A2047G mutation of 23S rRNA gene of B. pertussis. (ovid.com)
  • A putative metallo-β-lactamase gene presenting all of the conserved zinc-binding motifs that characterise the catalytic site was identified, in addition to a multidrug efflux pump of the RND family that could confer resistance to erythromycin, which is the antibiotic of choice for treating pertussis disease. (fiocruz.br)
  • A 120 bp long fragment from the IS481 gene from B.pertussis is amplified with specific primers and detected with a R6G labeled hydrolysis probe. (roche.com)
  • The adenylate cyclase gene of Bordetella pertussis: Molecular cloning and transcriptional analysis. (openrepository.com)
  • SERION ELISA classic Bordetella pertussis IgG/IgM/IgA are quantitative and qualitative tests for the detection of human antibodies in serum or plasma against Bordetella pertussis. (qedbio.com)
  • Evaluation of paired sera from six children with culture-proven pertussis demonstrated that antiadherence activity appeared in serum during convalescence from disease. (asm.org)
  • Highly sensitive real-time PCR assays and single-serum pertussis serology have been developed to overcome these limitations, but there are few data available on the relative sensitivities and specificities of such assays for pertussis diagnosis. (asm.org)
  • Serological assays, using one or two serum samples, have been developed to improve the sensitivity of the pertussis diagnosis, but they have a lower specificity than culture ( 3 , 9 , 20 , 25 ). (asm.org)
  • Proliferation occurred in autologous plasma or fetal calf serum, regardless of previous exposure to pertussis infection or immunization. (eurekamag.com)
  • A binding between the IgA antibodies of the serum and the immobilized Bordetella antigen takes place. (rapidtest.com)
  • During 2008-2012, a such as high rates of fever and local reactions, and vari- large outbreak of pertussis occurred. (cdc.gov)
  • CONCLUSION: Testing patients with respiratory symptoms using mPCR can improve early diagnosis of pertussis, ensure proper treatment, and may help with outbreak control. (medworm.com)
  • A pertussis outbreak was studied in a primary school in Xi'an, China, in March 2016. (ovid.com)
  • ECDC is addressing the harmonisation and improvement of pertussis diagnosis for surveillance and outbreak detection/monitoring in order to assure quality and comparability of data. (europa.eu)
  • This report published in Communicable Diseases Intelligence Volume 24, No 12, December 2000 contains the findings of the investigation of an outbreak of pertussis in Western Australia in 1999. (cancerscreening.gov.au)
  • In late 1999, an outbreak of Bordetella pertussis occurred in a small town in North-West Western Australia. (cancerscreening.gov.au)
  • We undertook an investigation to describe the outbreak and to identify strategies to minimise the impact of future pertussis outbreaks in Australia. (cancerscreening.gov.au)
  • This paper describes the epidemiology of the outbreak and outlines strategies for minimising the impact of future pertussis epidemics. (cancerscreening.gov.au)
  • However, our data suggest that it is suitable for inclusion in molecular epidemiological studies of the B. pertussis population or as a tool in outbreak investigations. (microbiologyresearch.org)
  • Pertussis is caused by Bordetella pertussis , a Gram-negative, pleomorphic coccobacillus, which is an exclusive human pathogen. (biomedcentral.com)
  • The most specific tests for diagnosis of pertussis were single serology and ptxA -Pr PCR, and the most sensitive diagnostic tool was the combination of IS 481 PCR with single serology. (asm.org)
  • Culturing B. pertussis from clinical specimens is the "gold standard" for diagnosis of pertussis, although this remains an insensitive method ( 12 , 13 ). (pubmedcentralcanada.ca)
  • Here we report that B. pertussis uses similar mechanisms for invasion of a variety of human cancer cells in vitro , and exhibits potent, invasion-dependent, cytotoxicity. (aacrjournals.org)
  • In a 30′ in vitro invasion assay, B. pertussis invaded human SKmel-23 melanoma cells at 20-30 times the rate for normal human melanocytes and fibroblasts. (aacrjournals.org)
  • Primary immunization with B. pertussis was also shown to generate lymph node cells which responded in vitro to secondary challenge with B. pertussis cells, FHA or PT. (eurekamag.com)
  • Is leukocytosis a predictor of mortality in severe pertussis infection? (qxmd.com)
  • In this study, we investigated whether whole-cell B. pertussis could inhibit allergic airway reactions in a murine model of asthma induced by ovalbumin (OVA). (nih.gov)
  • This study was performed to evaluate the immunogenicity, safety, and protection efficacy against Bordetella pertussis of the new Tdap vaccine in a murine model. (biomedcentral.com)
  • Intranasal murine model of Bordetella pertussis infection: II. (microbiologyresearch.org)
  • The causative agent of pertussis was identified and isolated by Jules Bordet and Octave Gengou in 1906. (wikipedia.org)
  • They also provided nasopharyngeal aspirates or, in a few centers, swab samples for culture and/or PCR detection of Bordetella pertussis and an acute blood sample for detection of anti-PT immunoglobulin G (IgG). (asm.org)
  • However, the rate of detection of B. pertussis by this medium was lower than that achieved with other conventional media ( 10 ). (pubmedcentralcanada.ca)
  • Providing a result for the detection of respiratory viruses, Mycoplasma, Chlamydophila & Pertussis in the Medical Admission when the patient is first seen, using point of care testing may avoid the issues highlighted, provide better quality of care, allow for better use of resources and reduce inappropriate antibiotic use and the development of antibiotic resistance. (isrctn.com)
  • What are the organism-specific therapeutic regimens for Bordetella pertussis bronchitis? (medscape.com)
  • Bordetella pertussis is BSL2 organism and should be considered a potential pathogen. (thelabrat.com)
  • B. pertussis has a stronger affinity for Dacron™ than for plain cotton wool or for treated cotton wool and its use improves recovery of the organism. (cmft.nhs.uk)
  • Concurrent culturing is used to differentiate species from B. pertussis and confirm the organism, while targeted DNA testing allows preliminary results to be reported the same day that the specimen is received. (loinc.org)
  • Our results show that B. pertussis is a dynamic organism that continues to evolve. (biomedcentral.com)
  • The data presented here provide support for CTB-Fim2 as a promising recombinant antigen against Bordetella pertussis infection. (biomedsearch.com)
  • The polymerase chain reaction (PCR) was recently added to conventional culture and serology for the diagnosis of Bordetella pertussis infection in a large vaccine efficacy trial in Germany. (ovid.com)
  • Effectiveness of rapid multiplex polymerase chain reaction for early diagnosis and treatment of pertussis. (medworm.com)
  • As part of this project ECDC is publishing two complementary guidance and protocols on Bordetella pertussis , the first on serological diagnosis of human infection and the second on the use of RT-PCR (real time polymerase chain reaction) for diagnosis of bordetella infections. (europa.eu)
  • On 26 November, B. pertussis was confirmed in both cases by polymerase chain reaction (PCR). (cancerscreening.gov.au)
  • Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3. (openrepository.com)
  • Is the Sequenced Bordetella pertussis strain Tohama I representative of the species? (pasteur.fr)
  • We conclude that Tohama I strain is not representative of the B. pertussis species. (pasteur.fr)
  • In the intranasal challenge test, inoculated B. pertussis was eradicated 7 days after infection. (biomedcentral.com)
  • Inflammation and infections as risk to prevent and control pertussis, but in many coun- factors for ischemic stroke. (cdc.gov)
  • 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. (asmscience.org)
  • Bordet-Gengou agar (BG agar) was the standard culture medium for isolation of B. pertussis but has the problem of low selectivity. (pubmedcentralcanada.ca)
  • Bordetella is a Gram-negative, pleomorphic, aerobic coccobacillus. (asmscience.org)
  • Pertussis has shown a striking resurgence in the United States, with a return to record numbers of reported cases as last observed in the 1950s. (asm.org)
  • Numerous studies have demonstrated that the B. pertussis population has changed since the 1950s. (biomedcentral.com)